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ABSTRACT 
Background: Urinary tract infections (UTIs) are common in veterinary medicine. 
Escherichia coli (E. coli) and Staphylococcus pseudintermedius (S. pseudintermedius) 
are the two most common causes of canine UTIs. The emergence of resistance to first 
line antimicrobials in these pathogens has posed challenges for veterinarians to treat 
their patients. Surveillance to detect the emergence of antimicrobial resistance (AMR) in 
companion animal pathogens is lacking in Western Canada. The efficacy of alternative 
agents for treating canine UTIs is similarly under investigated. The objective of this study 
was to determine the frequency and characterize the mechanisms of AMR among 
canine urinary pathogens in Saskatoon, Canada.  
Methods: Non duplicate canine urinary isolates (516 E. coli and 113 S. 
pseudintermedius) were collected from a diagnostic laboratory between November 1st, 
2014 and October 31st, 2018. Susceptibility testing was performed by agar dilution or 
broth microdilution against 15 antimicrobials belonging to 8 different drug classes and 
interpreted according to published breakpoints. Molecular characterization of resistance 
was performed by polymerase chain reaction (PCR) and epidemiological relationships 
were assessed by multi-locus sequence typing (MLST).  
Results: A substantial majority of isolates were susceptible to all antimicrobials tested. 
There was no significant increase in the frequency of resistance to any of the tested 
agents during the study period. Among E. coli, resistance to ampicillin was most 
common. Seven E. coli and four S. pseudintermedius were fosfomycin resistant. Overall, 
twelve isolates harbored CMY-2 type AmpC -lactamases, and seven produced CTX-M 
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type extended spectrum -lactamases (ESBLs). Of the fosfomycin resistant E. coli, one 
also possessed an CMY-2 type AmpC -lactamase. Of the fosfomycin resistant S. 
pseudintermedius, three were methicillin resistant. One isolate produced the aac(6′)- Ib-
cr gene. A single isolate belonging to the pandemic lineage ST131 was identified.  
Conclusion: Canine urinary E. coli in Saskatchewan remain largely susceptible to first 
line therapies, though resistance, particularly to the aminopenicillins, warrants continued 
monitoring. Fosfomycin represents a viable alternative option for treating uncomplicated 
cystitis in canine patients, although continued surveillance is required to identify 
changes in resistance. This is the first description of E. coli ST131 from a companion 
animal pathogen in Canada. 
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1. LITERATURE REVIEW 
1.1 An introduction to antimicrobial resistance 
 Antimicrobial resistance (AMR) is a normal microbial defense mechanism and 
many antimicrobial agents were first identified in microorganisms (fungi and bacteria) in 
nature1. In fact, through metagenomic analysis, genes encoding tetracycline, -lactam 
and glycopeptide resistance have been found in 30 000-year-old DNA right here in 
Canada2. Since the commercialization of penicillin in 1943, widespread antimicrobial use 
(AMU) in medicine and agriculture has imposed a selective pressure that has prompted 
the emergence and spread of resistance3. The link between antimicrobial consumption 
and the emergence and the dissemination of AMR strains has been well documented by 
epidemiological studies3. For example, in Europe, significant intercountry variation exists 
in the quantity of antimicrobials used to raise similar numbers of animals for human 
consumption4. A comparison of the quantity of antimicrobials consumed and the 
frequency of resistance in commensal E. coli from pigs, poultry and cattle in seven 
European countries suggests an overall strong positive correlation between AMU and 
AMR for many drug classes including fluoroquinolones, sulfonamides, aminopenicillins 
and third generation cephalosporins5. What’s more, rising concern for the contribution of 
environmental reservoirs to the AMR problem have been identified recently6. 
Specifically, the contamination of environments, including food and water sources, which 
are shared between humans and animals are increasingly investigated6–8. 
 Social factors also contribute to the AMR problem. Changes in health seeking 
behaviour create an increasing demand for antimicrobials, while the widespread 
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availability and lack of regulation in some countries has increased access to 
antimicrobials9. What’s more, the development of new agents is plagued by regulatory 
and financial constraints. While drugs for treating chronic diseases have significant 
financial return, the restricted use and significant cost associated with bringing 
antimicrobials to market has eliminated the financial incentive to develop new agents 
that is reflected in the relatively low number of companies currently cultivating new 
drugs10. Factor in the cost associated with regulatory requirements, including clinical 
trials and licensing, and the net value of developing a new antimicrobial is projected to 
be $-50 million, compared to +1 billion for a novel treatment for neuromuscular 
disease10. 
The social and economic consequences of AMR are equally as staggering. 
Projections from the European Centre for Disease Prevention and Control suggest that 
the 400 000 infections due to common multidrug resistant (MDR) infections result in 25 
000 deaths annually11. An additional 2 million people fall ill and 23 000 die each year 
due to similar infections in the United States12. Furthermore, the health care costs and 
productivity losses due to these infections in the U.S. are on the order of 20 and 55 
billion USD respectively13,14. While the development of AMR is rapid, reversing it is 
comparably slow. Important strategies to combat AMR include surveillance activities and 
restrictive policies to decrease AMU in humans, animals and agriculture1. 
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1.2 The clinical context of canine uropathogens 
1.2.1 Dogs as reservoirs for antimicrobial resistance  
When an animal takes antimicrobial drugs, its entire microbial community 
(including zoonotic, commensal and pathogenic bacteria) are exposed to the agent15. In 
fact, it has been shown that fecal E. coli from healthy and hospitalized dogs harbour 
resistance to one or more commonly prescribed antimicrobials, even in the absence of 
previous therapy16–20. Resistant bacteria are similarly isolated from extra intestinal sites. 
In a retrospective case series assembled from clinical data and laboratory specimens of 
MDR extra-intestinal E. coli from canine patients, the urinary tract accounted for 62% of 
isolates21. While one host may experience no adverse effects, these commensal 
populations represent an important reservoir for resistance genes that have the potential 
to cause disease under suitable circumstances. For example, the close contact between 
humans and their pets has implications for the sharing of resistant commensal and 
pathogenic bacteria between species, a phenomenon referred to as the Canine 
Reservoir Hypothesis19. Though the exact role of dogs in this zoonotic transmission 
cycle is poorly understood, examples supporting “strain sharing” between humans and 
companion animals are numerous in the literature. Among seven unique E. coli strains 
isolated from household members of a women with acute cystitis, the offending UTI 
strain was extensively shared, in time and space, between five members, including the 
family dog22. The sharing of canine fecal and urinary E. coli between dogs and humans 
has also been demonstrated by the simultaneous isolation of MDR and highly 
pathogenic strains from hospital workers and canine patients in a clinic environment23. 
This phenomenon is not restricted to E. coli. Human epidemic clones of MDR 
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Enterococci and methicillin resistant Staphylococcus aureus (MRSA) have also been 
isolated from pets in both the hospital and home environment24–27. Still others have 
identified an association between canine exposure to human or hospital environments 
and colonization with MRSA and Clostridium difficile28. At the molecular level, MDR 
Gram-negative pathogens carrying the same resistant genes have been isolated from 
dogs, cats, horses and people20,29. However, the presence of similar genes does not 
imply the isolation of identical strains. In reality, zoonotic transmission of resistant 
organisms from companion animals to humans is difficult to prove30.  
1.2.2 Antimicrobial use in canine patients 
Canadian data indicates that per year, dog owners are willing to spend almost 
double that of cat owners for veterinary services31. With this changing value of animals 
in society, more companion animals are receiving antimicrobial treatment. The most 
common infections for which antimicrobials are prescribed in dogs are skin, ear, 
respiratory and urogenital infections30,32. Concern for the potential of companion animals 
and livestock to harbour MRSA has led to a significant body of literature describing AMR 
among canine skin pathogens33–35. Urogenital infections remain relatively under 
investigated in comparison.  
Unlike human medicine, veterinarians both prescribe and dispense medication, 
including antimicrobials, at the individual practice level. As a result, there is no central 
body collecting data on veterinary prescriptions in Canada30. In fact, the only countries 
effectively tracking AMU in companion animals at a national level are Sweden, France, 
Finland, Denmark, Norway and the UK1,30,36–41. While concern for AMU in food animals 
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is not new, there are some patterns emerging in the prescribing practices of companion 
animal veterinarians that warrant attention. In the UK, the small animal veterinary 
surveillance network (SAVSNET) identified that roughly one third of consults with canine 
patients results in the prescription of antimicrobials42. The most commonly prescribed 
antimicrobial in this population was the potentiated -lactam, amoxicillin-clavulanate42–44. 
Among companion animals in the UK, the -lactam family accounted for three quarters 
of all antimicrobials prescriptions42. Surveillance efforts in Norway indicate similar AMU 
trends in pet animals. Since its approval for veterinary use in 1994, the proportion of 
amoxicillin- clavulanate prescriptions, relative to the total number of antimicrobial 
prescriptions in companion animals in Norway, rose from 1-84% in 201739. The 
fluoroquinolones are a family of broad spectrum and fully synthetic antimicrobials that 
were introduced into veterinary use in the 1990s45. According to national wholesale 
records in Denmark, a relatively small number of dogs and cats (1.2 million), consumed 
the same weight of fluoroquinolones and cephalosporins as food producing animals 
(including 23 million slaughter pigs, 130 million broiler chickens, and 1.2 million cattle 
and dairy cows), in 2003, pointing to the potential inappropriate use of these important 
drug classes among companion animal veterinarians46. 
No matter the motivation, AMU provides a selective pressure for the acquisition of 
resistance. This link between AMU and the development of resistance is particularly well 
documented for the fluoroquinolones. Among canine patients hospitalized in an 
intensive care unit, those that were treated with enrofloxacin were 25.6 times as likely to 
be colonized by a quinolone-resistant E. coli strain compared to animals in which 
antimicrobial were not used47. Similarly, an investigation of canine urinary E. coli isolates 
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in a U.S. teaching hospital revealed a significant increase in enrofloxacin resistant 
isolates that mirrored an increase in prescriptions the preceding year48. Concern about 
the overuse of certain families of antimicrobials in veterinary medicine, has led to the 
development of evidence-based consensus statements on disease specific AMU15,49,50. 
Factors guiding prudent use include awareness of the most common offending 
pathogens and their susceptibility patterns, as well as consideration for safety, and 
guided where possible by microbial culture and susceptibility testing against clinically 
relevant drugs51. Regulatory bodies in other regions have gone a step further and 
greatly restricted or banned the veterinary use of certain antimicrobials. In northern 
Europe, for example, the use of certain fluoroquinolones and third generation 
cephalosporins is tightly regulated. However, such restrictive policies are often only 
applied to food producing animals and are not extended to include companion animals15.  
1.2.3 A clinical description of canine urinary tract infections 
1.2.3.1 Etiology and pathogenesis 
Urinary tract infections (UTIs) affect between 5-27% of dogs that visit a 
veterinarian in their lifetime, with spayed females being over represented52,53. A UTI 
results from a temporary or permanent break in host defense, which allows microbes to 
invade, multiply and persist in the urinary tract52. Where there is spontaneous 
colonization of the urinary tract with compatible signs of lower urinary tract disease, a 
simple or uncomplicated infection exists54. While this terminology was previously used to 
describe infections in patients with no underlying comorbidities, structural, or functional 
abnormalities of the urinary tract, the most recent guidelines from the International 
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Society for Companion Animal Infectious Disease (ISCAID) assert that sporadic 
infections can still occur in these patient populations54. Complicated or recurrent 
infections, on the other hand, describe those that occur concurrently with an underlying 
condition, such as kidney disease or diabetes, which compromises host defense 
mechanisms. Complicated infections also encompass those that occur recurrently (three 
or more infections in a single year); or occur in a comparatively rare patient population; 
such as male dogs; or location; such as the kidneys or prostate52. Interestingly, feline 
cystitis used to be classified as “complicated” due to the frequent occurrence in senior 
patients, however, evidence that these infections are more difficult to manage is 
lacking54. 
Most often, invasion of the urinary tract occurs when microorganisms from the 
normal flora of the skin or gastrointestinal tract ascend the urethra to cause inflammation 
of the bladder (cystitis). Colonization of the upper urinary tract, including ureters and 
kidneys, is possible and is referred to as pyelonephritis52,55. However, for the purposes 
of this review, UTI is synonymous with cystitis and infections of the lower urinary tract.  
The most common etiological agent in canine UTI cases is the Gram-negative 
enteric bacteria E. coli belonging to the larger Enterobacteriaceae family. Though 
estimates vary, E. coli represent between one third and one half of positive urine 
cultures52,56. The Gram-positive cocci Staphylococcus, Streptococcus and Enterococcus 
spp, which normally colonize the canine skin, occur less frequently. Additional 
pathogens identified in canine UTI cases include the Enterobacteriaceae Proteus, 
Klebsiella and Enterobacter spp57. The most common offending agents in cases of 
canine UTIs are summarized in Table 1.151,57. 
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Table 1.1: The ten most frequent pathogens cultured in canine urinary tract infections57 
Microorganism Prevalence (%) 
E. coli 44.1 
Staphylococcus spp. 11.6 
Proteus spp. 9.3 
Klebsiella spp. 9.1 
Enterococcus spp. 8.0 
Streptococcus spp. 5.4 
Pseudomonas spp. 3.0 
Mycoplasma spp. 2.5 
Enterobacter spp. 2.3 
Providencia spp. 1.0 
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1.2.3.2 Diagnosis 
Clinically, a diagnosis of UTI is made based on a combination of compatible 
findings in the history, physical exam, and ancillary tests58. Clinical signs of cystitis 
include frequent or painful urination, straining to urinate, urinating blood or inappropriate 
urination (accidents in the house)58. While physical examination is often unremarkable, a 
patient side visual and microscopic evaluation of urine, known as urinalysis, may reveal 
elevated protein and red blood cells (hematuria) with or without elevated white blood 
cells (pyuria) and bacteria (bacteriuria), which are suggestive of infection58. However, 
the submission of a urine sample, obtained by cystocentesis, for aerobic culture and 
susceptibility testing is required for definitive diagnosis of UTI, to guide antimicrobial 
prescription and confirm infection50,58.  
1.2.3.2.1 Antimicrobial susceptibility testing  
Susceptibility testing involves exposing bacteria to a range of concentrations of a 
panel of drugs to detect the presence of resistance and to confirm susceptibility to a 
drug of choice59. Both qualitative and quantitative methods exist. For example, disk 
diffusion is a technique commonly employed in veterinary diagnostic labs. By this 
method bacteria are designated simply as susceptible, intermediate or resistant59. This 
fact limits the information which may be generated from the results. In contrast, 
quantitative susceptibility testing methods, which have become standard in medical 
diagnostic laboratories, involve the inoculation of a standard number of bacteria in broth 
onto 96 well trays or agar plates containing serial dilutions of various antimicrobials, 
followed by overnight incubation and the determination of the minimum concentration 
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that inhibits bacterial growth (known as minimum inhibitory concentration or MIC)59. MIC 
values (measured in g/mL) can be compared to published breakpoint for each drug-
bug combination tested. Bacteria exhibiting MICs above this breakpoint value are 
defined as clinically resistant. A “susceptible” result indicates that an organism should be 
readily treated with the corresponding antimicrobial using the normal dosage 
recommendations for that type of infection and species. Conversely, a “resistant” 
organism is not anticipated to respond to therapy at the concentration of antimicrobial 
achieved with normal dosages for the infection under investigation58. With these 
quantitative methods it is possible to detect both reduced susceptibility and clinical 
resistance. Epidemiological cut-off values have been published, which indicate the 
highest MIC displayed by a wild type member of a bacterial species, which is devoid of 
phenotypically detectable acquired resistance. An elevated MIC relative to this value 
indicates the presence of acquired resistance that is not typical for that bacteria, a fact 
that is not as readily detected by qualitative susceptibility testing methods. Both agar 
dilution and broth microdilution techniques have been highly standardized and are 
available in a number of commercially prepared formats59. It is recommended that the 
diagnostic laboratory perform and interoperate susceptibility testing according to 
published standards such as those available through the Clinical Laboratory Standards 
Institute (CLSI) using criteria specific to urinary pathogens where available58. These 
values have taken into account microbiological, pharmacologic and clinical data to 
synthesize the efficacy of certain drug-bug combinations for the infection under 
investigation50. 
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1.2.3.3 Treatment 
Antimicrobials have historically been the mainstay of treatment in cases of 
sporadic or uncomplicated canine cystitis. However, the most recent ISCAID guidelines 
suggest that initial treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) may be 
appropriate with the addition of antimicrobials if clinical signs worsen54. Empirical 
treatment for sporadic cystitis is appropriate only in cases when previous AMU is limited 
and the causative agent and its most likely susceptibility are predictable54. Options 
include members of the -lactam class; such as the aminopenicillin amoxicillin, 
preferably in a formulation without the -lactamase inhibitor clavulanic acid. The 
potentiated sulfonamide trimethoprim-sulfamethoxazole (SXT), while frequently used 
historically, has fallen out of favour due to its significant profile of adverse effects50,58. 
Second tier or alternative therapies with a broader spectrum of activity, such as 
nitrofurantoin, fluoroquinolones (enrofloxacin, ciprofloxacin), chloramphenicol, 
doxycycline and fosfomycin should be reserved for cases where laboratory results 
indicate a lack of susceptibility to empirical treatments54. In general, it is considered 
inappropriate to prescribe third generation cephalosporins, carbapenems, 
aminoglycosides or fluoroquinolones in cases of sporadic cystitis given their relative 
importance in treating human infections, coupled with increasing frequencies of 
resistance54.  
The duration of therapy in UTI cases is a contentious topic in both human and 
veterinary medicine. Historically, in veterinary patients, therapy is long (7-14 days) 
compared to similar infections in humans (3-5 days)58,60. The limited veterinary literature 
available indicates that short duration (3 day) therapy with SXT and enrofloxacin were 
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equivalent to 10-14 days of therapy with amoxicillin-clavulanate or cephalexin in treating 
uncomplicated cystitis in canine patients61,62. In both cases, these studies compared 
short duration therapy with one agent to long duration therapy with an antimicrobial 
belonging to a different class. Unfortunately, studies comparing the same drug at 
different durations of therapy are lacking in veterinary medicine. Despite relatively 
limited evidence, ISCAID’s recommended duration of therapy has been recently updated 
to 3-5 days54. In addition to culture and susceptibility results, these guidelines encourage 
veterinarians to educate themselves on the pathogen and AMR trends in their area, as 
well as principles of prudent use, to further guide antimicrobial therapy in UTI 
cases15,49,50,54. Treatment guidelines for canine UTIs are summarized in Table 1.2. 
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Table 1.2: ISCAID guidelines for the treatment of bacterial cystitis in dogs and cats54 
Drug Class Dose Comments 
Empirical treatment 
Amoxicillin -lactam- aminopenicillin 11-15 mg/kg PO q12h Good first line option. Excreted in 
the urine predominantly in its active 
form. Achieves high concentrations 
in the urine 
Amoxicillin-clavulanate Potentiated -lactam 12.5-25 mg/kg PO q12h Good first line choice when regional 
resistance to amoxicillin is high. No 
significant evidence for superiority 
over amoxicillin alone for 
uncomplicated cystitis. Achieves 
high concentrations in urine  
Trimethoprim-
sulfamethoxazole 
Potentiated sulfonamide 15-30 mg/kg PO q12h 
 
Good first line option 
Second line treatment 
Nitrofurantoin Nitrofurans 4.4-5 mg/kg PO q8h Good choice for uncomplicated 
cystitis particularly when multidrug 
resistant pathogens is involved 
Enrofloxacin/Ciprofloxacin/ 
Marbofloxacin/Orbifloxacin/ 
Pradofloxacin 
Fluoroquinolone 5-20 mg/kg q24h  
 
25-30 mg/kg PO q24h 
 
2.7-5.5 mg/kg PO q24h 
 
2.5-7.5 mg/kg PO q24 
 
3-5 mg/kg PO q24. 
Reserved for multidrug resistant 
infections 
Chloramphenicol Phenicol 40-50 mg/kg PO q8h Reserved for multidrug resistant 
infections 
Doxycycline Tetracycline 5 mg/kg PO q12h Reserved for infections that are 
resistant to drugs that achieve high 
urine concentrations 
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Fosfomycin Phosphonic acid 
derivative 
40 mg/kg PO q12h Reserved for multidrug resistant 
infections 
Not Recommended 
Imipenem/Meropenem -lactam-carbapenem 5 mg/kg IV/IM q6-8h 
 
8.5 mg/kg q12 SC or q8 
IV 
Not recommended for routine use 
for uncomplicated cystitis 
Cefovecin -lactam- third generation 
cephalosporin 
8 mg/kg SC once Not recommended for routine use 
for uncomplicated cystitis as 
duration and spectrum are longer 
than is typically needed. No oral 
option  
Amikacin Aminoglycoside 15-30 mg/kg IV/IM/SC 
q24h 
Not recommended for routine use 
for uncomplicated cystitis  
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1.2.4 Cystitis in human medicine 
In the U.S. between 2007 and 2009, antimicrobials were prescribed during 101 
million (10%) outpatient physician visits each year63. Broad-spectrum agents were used 
during 61% of these visits with fluoroquinolones (25%), macrolides (20%) and 
aminopenicillins (12%) being prescribed most frequently63. The most common conditions 
for which antimicrobials were given included respiratory conditions, skin/mucosal 
conditions and UTIs63. Cystitis is a common presenting complaint in human medicine, 
effecting approximately 1 in 3 women by early adulthood and necessitating the use of 
antimicrobials55. Similar to the case in dogs, E. coli is the most common pathogen in 
uncomplicated cystitis cases55.  
1.2.4.1 Treatment guidelines from the human literature 
In 2010, the Infectious Diseases Society of America (IDSA) updated their clinical 
guidelines for UTI treatment64. In general, there are significantly more options approved 
for the treatment of sporadic cystitis in human medicine. First line empirical treatments 
include the older agents fosfomycin, and nitrofurantoin as well as SXT and 
pivmecillinam. Second line treatment options include ciprofloxacin64. In contrast to the 
case in veterinary medicine, amoxicillin is no longer recommended, owing to its 
relatively poor efficacy, coupled with the high frequency (>20%) of resistance identified 
in previous guidelines65,66. Similar to veterinary guidelines, the IDSA no longer 
recommends fluoroquinolones for empirical treatment of UTIs citing its relative 
importance for infections other than cystitis64. A summary of IDSA treatment guidelines 
is given in Table 1.3.  
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Table 1.3: IDSA guidelines for the treatment of sporadic bacterial cystitis in women64 
Drug Class Dose Duration Comments 
Empirical treatment 
Nitrofurantoin Nitrofuran 100 mg PO 
q12 for 5 days 
5 days Good first line choice. 
Comparable efficacy to 
trimethoprim-
sulfamethoxazole 
Fosfomycin Phosphonic acid 
derivative 
160/800 mg 
PO q12 
3 days Good first line choice. May 
have inferior efficacy 
compared with standard 
short- course regimens 
according to FDA 
Trimethoprim-
sulfamethoxazole 
Potentiated sulfonamide 3 g PO once - Good first line choice. Use 
only in areas where local 
resistance rates are <20% 
Pivmecillinam -lactam- extended 
spectrum penicillin 
400 mg PO 
q12 
3-7 days Limited availability (not 
licensed in North America) 
Second line treatments 
Ciprofloxacin/ofloxacin/ 
levofloxacin 
Fluoroquinolone - 3 days Not recommended for 
routine use. Generally 
reserved for important uses 
other than cystitis 
Amoxicillin-clavulanate, 
cefdinir, cefaclor, and 
cefpodoxime-proxetil  
-lactams - 3-7 days Generally inferior efficacy 
compared to other agents. 
Only recommended when 
agents cannot be used 
Not Recommended 
Amoxicillin -lactam-aminopenicillin - - Not recommended for 
routine use for 
uncomplicated cystitis due to 
widespread resistance and 
low efficacy 
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1.2.4.2 Alternative antimicrobials for the treatment of sporadic cystitis 
Given the frequency with which antimicrobials are used to treat cystitis, 
surveillance initiatives for AMR in urinary pathogens have become common place in 
human medicine. Programs such as the North America Urinary Tract Infection 
Collaborative Alliance (NAUTICA) and the Study for Monitoring Antimicrobial Resistance 
Trends (SMART) have identified the rapid emergence and spread of resistance among 
community acquired urinary E. coli in Canada and the U.S., which has necessitated the 
investigation of alternative treatment options including the re-evaluation of older 
agents67–72. In fact, susceptibility testing in a 2013 U.S. study of 120 community acquired 
clinical E. coli isolates against six oral antimicrobials (azithromycin, doxycycline, 
minocycline, chloramphenicol, fosfomycin, and rifampin) considered older or alternative 
by current standards, revealed that resistance to fosfomycin was astonishingly rare, with 
in vitro susceptibility rates between 98-99%73. 
Fosfomycin is a bactericidal phosphonic acid derivative that was originally 
discovered in Spain in 196970,74. Sold under the trade name Monurol, fosfomycin is 
approved exclusively for the treatment of uncomplicated cystitis in the U.S. and 
Canada75. However, there is a general lack of availability in parts of North America and 
many countries in Europe76. Fosfomycin is indicated for the treatment of infections 
caused by susceptible strains of E. coli and E. faecalis and is administered as a single 
oral dose containing 3 g of fosfomycin tromethamine75. This dosing regime is attractive 
clinically from the context of patient convenience and compliance, while simultaneously 
minimizing selective pressure for resistance as uropathogens are exposed for a 
relatively short period. This fact coupled with fosfomycin’s unique mechanism of action 
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are reflected in the astonishing rates of susceptibility among community acquired 
uropathogens77. Fosfomycin has a broad spectrum of activity against both Gram-
negative (Enterobacteriaceae) and Gram-positive (Staphylococcus spp. and 
Enterococcus spp.) pathogens that has been demonstrated in both in vitro and in vivo 
studies69,71.  
A 2010 study reviewed the microbiological and clinical literature regarding the 
efficacy of fosfomycin against Enterobacteriaceae isolates, including those with MDR 
phenotypes producing extended spectrum -lactamase (ESBL) enzymes78. Of 13 
microbiological studies, ten looked exclusively at community or hospital acquired UTIs 
where the vast majority of isolates were ESBL producing E. coli. All ten studies reported 
susceptibility rates in excess of 90%79–88. The authors concluded that among the 
species studied, E. coli was the most susceptible (96.8% of ESBL producing isolates). 
What’s more, rates of resistance were higher overall among hospital acquired compared 
to community acquired strains78. Of the four clinical studies reviewed, two involved 
treatment of ESBL producing community and/or hospital acquired uropathogenic E. 
coli87,89. One study assessing fosfomycin in a three-dose protocol for the treatment of 
uncomplicated cystitis in patients who cultured positive for ESBL producing E. coli, 
reported clinical and microbiological cure rates of 94% and 78%87. Overall the 
cumulative cure rate (indicated by negative culture) in these studies was 93.8% causing 
the authors to conclude that fosfomycin is a valid and potentially useful treatment option 
for uncomplicated cystitis caused by ESBL producing E. coli78. The efficacy of 
fosfomycin was further assessed for the prevention of UTI recurrence in 166 patients 
compared to a placebo group. Patients in the treatment group received 3 g of fosfomycin 
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tromethamine every 10 days for 6 months. At one year follow up, the fosfomycin treated 
group reported a reinfection rate of 0.14 infections per year compared to 2.97 infections 
per year in the placebo group90. Additional recent studies have confirmed the efficacy of 
two and three dose fosfomycin protocols in both uncomplicated and/or complicated 
cystitis91–93. A single Canadian study assessing the in vitro activity of fosfomycin against 
a nationally representative sample of urinary E. coli concluded that 99.4% of isolates 
were susceptible to fosfomycin94. Susceptibility in MDR strains ranged from 95-100% 
among ESBL producers and 97-100% among AmpC -lactamase producers94. Overall 
Fosfomycin represents a promising and efficacious option for the empirical treatment of 
UTIs caused by E. coli.  
Despite its enthusiastic use in human medicine, literature documenting the 
efficacy of fosfomycin in treating canine infections is scarce. It is well known that 
fosfomycin tromethamine is predominantly excreted unchanged in the urine of humans, 
lending to its value in treating UTIs70,74. A single veterinary study investigating the 
pharmacokinetic properties of fosfomycin disodium in dogs failed to investigate urine 
concentrations, focusing instead on serum concentration and serum values that reflect 
kidney function95. What’s more, the investigated agent is a parenteral formula when in 
reality the oral compound, fosfomycin tromethamine is used to treat cystitis. Canine 
subjects were administered fosfomycin at two different doses intravenously, 
intramuscularly, subcutaneously and orally once. The authors concluded that the only 
useful route, which achieved adequate plasma concentrations of fosfomycin was 
subcutaneous injection95. Given that fosfomycin is not currently approved for use in 
veterinary medicine, clinical trials have not been done in canine patients.  
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In vitro studies demonstrating the microbiological efficacy of fosfomycin against 
Enterobacteriaceae are scarce in veterinary medicine. A single study investigated the 
susceptibility of 200 clinical E. coli isolates from canine and feline infections; including 
UTIs, found astonishing rates of susceptibility, with just 3/200 isolates reported as 
resistant96. Experimental isolates (n=75) collected in the same study from the feces of 
dogs treated with either enrofloxacin or amoxicillin for 7 days exhibited 100% 
susceptibility to fosfomycin96. One other in vitro study investigating the susceptibility of 
E. coli isolated from bitches with pyometra found that 100% of isolates were 
susceptible97. The remainder of the veterinary literature investigating fosfomycin focuses 
on its efficacy against methicillin resistant Staphylococcus pseudintermedius (MRSP) in 
canine pyoderma cases. Susceptibility rates reported in these studies ranged from 77-
100% among clinical isolates98,99. Interestingly, there has been a single case report of 
renal insufficiency in a cat following fosfomycin administration100.  
 
1.3 Antimicrobial resistance in veterinary medicine 
Antibiotics are compounds produced by living organisms that inhibit microbial 
growth. The broader term antimicrobial, includes both synthetic and naturally derived 
compounds that exhibit activity against microorganisms, including antibacterials, 
antivirals, anthelminthics and antifungals49. The following section outlines the 
mechanisms of action of clinically important antimicrobials and provides a discussion of 
the most common mechanisms of resistance encountered against those agents used 
most commonly to treat canine cystitis. 
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1.3.1 Mechanisms of antimicrobial action 
Antimicrobials can be grouped broadly based on their primary site of action in the 
bacterial cell. Antimicrobial mechanisms of action include protein synthesis inhibition, 
cell wall synthesis inhibition, inhibitors of DNA metabolism and disruption of cell 
membrane structure49. Additional compounds have also been developed to combat 
highly prevalent AMR mechanisms including the group of compounds known to inhibit -
lactamase enzymes (clavulanic acid, sulbactam, tazobactam)101. Antimicrobials vary in 
their spectrum of activity. While some exhibit specific activity against Gram-negative or 
Gram-positive microorganisms, others have a broad spectrum of activity against many 
different microbial species49.  
1.3.1.1 Protein synthesis inhibitors 
Protein synthesis inhibitors act on the cellular machinery involved in translating 
mRNA into polypeptide chains (proteins). The primary site of action of these drugs is the 
ribosome101. In contrast to the larger 80S ribosome in eukaryotes, bacteria have a 70S 
ribosome that consists of a 50S subunit and a smaller 30S subunit101. Either of these 
may be the primary site of action of antimicrobials. Examples of protein synthesis 
inhibitors approved for use in veterinary species include the aminoglycosides 
(gentamicin and amikacin), macrolides (erythromycin, clarithromycin and clindamycin), 
tetracyclines (oxytetracycline), phenicols (chloramphenicol), streptogramins and 
lincosamides101. 
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1.3.1.2 Cell wall synthesis inhibitors  
Cell wall synthesis inhibitors target the enzymes and substrates involved in 
peptidoglycan synthesis, a structure that is absent in eukaryotes and specific to 
bacteria101. Important classes, which act by this mechanism include the very large -
lactam family, fosfomycin and glycopeptides (vancomycin)101. -lactams can be further 
broken down into penicillins (amoxicillin, ampicillin), cephalosporins (cephalexin, 
ceftiofur, ceftriaxone), cephamycins (cefoxitin), monobactams (aztreonam) and 
carbapenems (meropenem)102. These compounds act similarly owing to a common four 
membered ring in their structure, by binding penicillin binding proteins involved in cell 
wall synthesis101,102. In fact, this common structure has implications for the acquisition of 
resistance to this class that has resulted in the development of many iterations of 
cephalosporins that can be grouped into different generations based on their 
structure101. For example, the extended spectrum cephalosporins (ESC), initially 
developed in the 1980s, include a bulky oxyimino subgroup in their structure, which, at 
least temporarily evaded the development of resistance to these compounds102.  
Carbapenems are a critically important antimicrobial class for the last resort treatment of 
human infections and so are not widely used in veterinary medicine103.  
In addition to the cell wall, bacteria possess a cell membrane which can be the 
target of antimicrobial compounds. The polymyxins (ex. Colistin) are one such example 
of a drug class, which exert their mechanism of action by interfering with cell membrane 
structure101. 
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1.3.1.3 Inhibition of DNA metabolism 
DNA metabolism encompasses both DNA replication and folic acid metabolism. 
The fluoroquinolones and rifampin are examples of compounds which interfere with 
enzymes involved in DNA replication101,103. While rifampin acts on the DNA polymerase 
that synthesizes new DNA strands, fluoroquinolones act on DNA gyrases involved in 
relaxing the supercoiled structure of DNA prior to replication101,103. Antimicrobials that 
competitively inhibit the synthesis of folic acid include the sulfonamides 
(sulfamethoxazole) and trimethoprim101. 
1.3.1.4 -lactamase inhibitors 
Fully synthetic antimicrobial compounds have also been developed to specifically 
target certain enzymes produced by AMR bacteria. These -lactamase inhibitors (ex. 
clavulanic acid, tazobactam, sulbactam and boric acid) are always administered in 
combination with -lactam antimicrobials and exert their action by irreversibly binding -
lactamase enzymes capable of breaking down the -lactam antimicrobial, thus making 
these drugs more effective101. 
1.3.2 Mechanisms of antimicrobial resistance 
Antimicrobial resistance is a natural phenomenon that predates the clinical use of 
antimicrobial compounds. Certain microbes are intrinsically resistant to the action of 
antimicrobial drugs due to their inherent structure or physiology. For example, 
Mycoplasma spp. are resistant to the action of cell wall synthesis inhibitors (ex. -
lactams) as they lack a cell wall49. On the other hand, AMR can also be acquired. 
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Microorganisms may develop resistance by spontaneous mutations in their 
chromosomal DNA, for example through the occurrence of a single nucleotide 
polymorphisms (SNP). However, bacteria also have the ability to acquire resistance 
genes horizontally form other microorganisms49. Horizontal gene transfer may occur via 
transformation, transduction or conjugation on plasmids or transposons. Plasmids are a 
form of extrachromosomal DNA that replicate apart from the chromosome and that are 
freely exchanged between and within bacterial species49. Transposons, are pieces of 
chromosomal DNA, which are capable of excising themselves from the DNA of a donor 
organism and inserting into either the plasmid or chromosomal DNA of a recipient52. 
Transformation refers to the uptake of naked DNA from the environment, while 
transduction involves the acquisition of resistance genes from viruses. Finally, 
conjugation involves the transfer of mobile genetic elements between two bacteria in 
direct contact101.  
Mechanisms of AMR fall into five major categories; i) changes in cell membrane 
permeability or transporters decreasing antimicrobial uptake ii) expression of efflux 
pumps increasing the removal of antimicrobials from the cell iii) the acquisition of 
enzymes that are capable of hydrolyzing or otherwise inactivating antimicrobials iv) 
alterations of the antimicrobial target by mutation or target protection v) immunity and 
bypass of antimicrobial sites of action caused by the over expression of antimicrobial 
targets or the development of alternative metabolic pathways101,103. The following 
sections discuss each of these mechanisms in detail, using E. coli as an example.  
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1.3.2.1 Decreased uptake 
Intrinsic differences in permeability exist between bacterial species. For example, 
the outer membrane of Gram-negative bacteria (which is absent in Gram-positive 
bacteria) provides an additional permeability barrier to the uptake of antimicrobial 
agents. These organisms represent a particular challenge in developing new treatment 
options101. Decreased uptake of the cell wall synthesis inhibitor fosfomycin is a common 
mechanism of resistance in E. coli. This agent is reliant on two different transport 
systems (a hexose phosphate transporter and a glycerol-3-phosphate transporter) for 
uptake into the cell76. Acquired mutations in the genes encoding one or both of these 
transporters results in resistance103. What’s more, outer membrane protein (OMP) 
deficient strains of Enterobacteriaceae, including E. coli, have also emerged recently, 
which confer resistance to the critically important carbapenem -lactams104,105.   
1.3.2.2 Efflux pumps 
Various efflux pumps have been described, which are capable of transporting 
different antimicrobial classes. While some, such as the fluoroquinolone efflux pump 
encoded by qepA, are highly specific, others are capable of transporting a wide variety 
of compounds. For example, the oqxAB gene encodes a transmembrane protein that is 
capable of transporting quinolones, tetracyclines chloramphenicol and 
trimethoprim103,106. Genes encoding these transporters are often acquired by horizontal 
gene transfer. For example, in E. coli, tetracycline drugs may be removed from the cell 
by acquisition of a variety of tet genes. To date, nine genes encoding tetracycline 
transporters have been identified (tetA, tetB, tetC, tetD, tetE, tetG, tetJ, tetL and tetY)103. 
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Examples of efflux pumps against other drug classes include the floR gene which 
encodes a phenicol transporters103.    
1.3.2.3 Enzymatic inactivation 
Currently, AMR mediated by enzymatic inactivation is one of the most important 
mechanisms threatening the clinical utility of antimicrobials. These enzymes exist in both 
Gram-negative and Gram-positive organisms52,107. For example, penicillinase enzymes 
acquired by certain strains of Staphylococci confer resistance to penicillin 
antimicrobials52. However, particularly among Gram-negative pathogens, inactivating 
enzymes are both prevalent and permissive. Enzymes have been identified encoded on 
transferrable genetic elements, which confer resistance to -lactams (-lactamases), 
aminoglycosides (aminoglycoside aminotransferases), fosfomycin (fosA, fosB, fosX), 
tetracyclines (tetX), chloramphenicol (cat genes) and fluoroquinolones (aac(6’)-Ib-cr)103. 
1.3.2.4 Target alterations 
Antimicrobial sites of action can be altered in two distinct ways. Chromosomal 
mutations in the genes encoding the target can lead to decreased affinity or activity of 
an antimicrobial. For example, Gram-negative organisms develop decreased 
susceptibility to fluoroquinolones by acquiring mutations in the parC and gyrA genes 
which encode domains of the DNA gyrase enzymes upon which fluoroquinolones act103. 
Mutations in the rmt and armA genes have also been described, which confer resistance 
to aminoglycosides103. It is also possible for an antimicrobial target to become modified 
by some acquired mechanism (a protein or enzyme) that protects it from the activity of 
the antimicrobial. Examples where resistance is conferred in this manner have been 
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described in E. coli for tetracyclines (tetM and tetW), fluoroquinolones (qnrA, qnrB, qnrC, 
qnrD and qnrS), phenicols, macrolides and oxazolidinones (cfr)103.     
1.3.2.5 Immunity and bypass 
The sulfonamides and trimethoprim are the most important example of an 
antimicrobial class that exert their action by interfering with cellular metabolism, 
specifically folic acid synthesis103. Resistance to either of these compounds in isolation 
can occur in Enterobacteriaceae through the acquisition or enzymes which provide an 
alternative pathway to complete folic acid synthesis. For example, while the 
sulfonamides are active against dihydrofolate reductase (encoded by dfr genes), 
trimethoprim is active against dihydropteroate synthetase (encoded by sul genes). 
Therefore, the acquisition of sul genes confers resistance to sulfonamides while the 
acquisition of dfr genes confer resistance to trimethoprim103. In order to more effectively 
target folic acid synthesis, “potentiated” sulfonamide formulations were developed which 
combine these two agents, for example, trimethoprim-sulfamethoxazole. 
1.3.3 Antimicrobial resistance in urinary E. coli: A clinical perspective 
The mechanisms responsible for AMR are diverse across microbial species. 
However, antimicrobial exposure in any context provides a common selective pressure 
for the emergence and dissemination of resistance in bacterial population. From a 
clinical perspective, certain pathogens and antimicrobials are more important than 
others3. According to the Center for Disease Control and Prevention (CDC) ESBL 
producing Enterobacteriaceae pose a serious threat to public health in the context of 
AMR3. Within the family Enterobacteriaceae, the versatile organism E. coli, is of interest 
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for a variety of reasons. First, despite being intrinsically susceptible to many clinically 
relevant antimicrobials, E. coli has an exceptionally plastic genome and is able to both 
acquire and spread resistance genes by horizontal gene transfer. E. coli, therefore 
represents an important reservoir of resistance genes within microbial communities103. 
Second, the transmission of E. coli between and within different hosts can occur by a 
variety of mechanisms including direct contact or via contaminated food and water 
sources103. Third, E. coli represent both a commensal organism and pathogen. The 
pathogenic potential of E. coli varies significantly and can be classified into different 
pathotypes based on the anatomic site of disease103. While the majority of E. coli that is 
ubiquitous in the gastrointestinal tract of humans and animals are benign, some strains 
are capable of causing disease (diarrhea and colitis) and belong to pathotypes known as 
enterotoxigenic E. coli (ETEC). This is in contrast to extra-intestinal pathogenic E. coli 
(ExPEC), which migrate from the digestive tract to extra-intestinal sites, such as the 
urogenital tract and blood stream, to cause disease103. The E. coli genome normally 
comprises between 4,000 and 5,000 genes, of which approximately 3,000 are 
conserved across strains. The remainder are responsible for the spectrum of 
pathogenicity observed among E. coli isolates and comprise virulence and colonization 
determinants that improve the disease-causing potential of their host103. 
As a ubiquitous organism with genetic plasticity and significant pathogenic 
potential, there are many resistance mechanisms worth investigating in E. coli. The most 
relevant currently are ESBLs, carbapenemases, and plasmid-mediated quinolone 
resistance (PMQR) genes, which are present on mobile genetic elements that are 
exchanged between and within bacterial species103. Additional transmissible resistance 
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mechanisms are described with increasing frequency against fosfomycin, which has re-
emerged in human medicine for the treatment of sporadic cystitis103. This section 
describes drug specific resistance mechanisms in E. coli in more detail from the 
perspective of veterinary medicine.  
1.3.3.1 -lactams 
The -lactams are a large drug class that includes penicillins, cephalosporins, 
monobactams and carbapenems102.They are named for the common presence of a four 
membered -lactam ring102. Enzymatic inactivation by β-lactamases are the most 
important mechanism of resistance to this drug class, particularly among 
Enterobacteriaceae103. These enzymes are of particular concern for a number of 
reasons. First, they target a common structural component in β-lactam drugs, the β-
lactam ring and thus, they display activity against a wide variety of these compounds108. 
Second, -lactamases are both chromosomally and plasmid encoded and therefore 
have the potential to be freely exchanged between and within bacterial species109–111. 
Third, there is great diversity among -lactamases in terms of their spectrum of activity 
against β-lactam drugs109. These enzymes are classified most commonly using the 
Ambler system, which takes into consideration their molecular structure and amino acid 
sequence112. However, functional classifications based on hydrolytic spectra also 
exist113. Ambler class A, C and D enzymes, though significantly different in their amino 
acid sequence, contain a common serine residue in their active site. Class B enzymes, 
on the other hand, utilize a divalent zinc ions for substrate hydrolysis113,114.  Class A 
includes the narrow spectrum penicillinase type -lactamases (TEM-1), ESBLs and KPC 
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type enzymes. Class B contains the metallo--lactamases, while Class C includes 
plasmid mediated AmpC -lactamases. Finally, Class D includes the oxacillinases, also 
known as OXA-48 like enzymes110,115,116. Based on spectrum of activity these enzymes 
are more accurately divided into ESBLs, carbapenemases (including, KPC, metallo -
lactamases, and OXA-48 like enzyme) and plasmid mediated AmpC -lactamases110. 
The major classes of -lactamases described in E. coli are outlined in Table 1.4110,115.  
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Table 1.4: An overview of -lactamase enzymes in E. coli110,115 
Enzyme Classification Example Phenotype Inhibition 
Extended spectrum -
lactamases (ESBLs) 
Class A CTX-M, SHV, TEM Penicillins 
Cephalosporins 
Monobactams 
Clavulanic acid 
Tazobactam 
Sulbactam 
AmpC -lactamases Class C CMY, FOX, ACT, 
MOX, ACC, DHA  
Penicillins 
Cephalosporins 
Monobactams 
Cephamycins 
Cloxacillin 
Boronic acid 
Carbapenemases 
Metallo-β-lactamases 
(MBLs)  
 
Class B IMP, VIM, NDM Penicillins 
Cephalosporins 
Cephamycins 
Carbapenems 
Metal chelators 
(EDTA) 
KPC 
carbapenemases  
Class A KPC Penicillins 
Cephalosporins 
Cephamycins 
Carbapenems 
Clavulanic acid 
(weak) 
Tazobactam 
Boronic acid 
OXA-β-lactamases Class D OXA-48, OXA-181 Penicillins 
Carbapenems 
Clavulanic acid 
(weak) 
NaCl 
 
 
 - 32 - 
1.3.3.1.1 Extended spectrum -lactamases 
ESBLs are capable of hydrolyzing even those extended-spectrum -lactams that 
had been modified to confer resistance to the first generation of -lactamase 
enzymes110. They exhibit activity against penicillins, monobactams and cephalosporins, 
including ESCs, but remain susceptible to cephamycins, carbapenems and -lactamase 
inhibitors such as clavulanic acid110. SHV, TEM and CTX-M type ESBLs are among the 
most common. While SHV and TEM type enzymes dominated originally, since the 
beginning of the 21st century, CTX-M type enzymes have become most 
prevalent76,110,117.  
1.3.3.1.2 AmpC -lactamases 
Class C -lactamases (or AmpC -lactamases) are widespread in bacterial 
species and may be both chromosomally and plasmid encoded116. Specifically, E. coli 
tend to possess chromosomally encoded, non-inducible AmpC -lactamases which may 
be upregulated by mutations in the promoter76,110,118. E. coli may also acquire plasmid 
mediated AmpC -lactamases of which the CMY-2 type is most common116,119. AmpC -
lactamases confer resistance to penicllins, cephalosporins, monobactams and 
cephamycins, as well as the “classic” -lactamase inhibitors such as clavulanic acid. 
However, they remain susceptible to fourth generation cephalosporins and 
carbapenems76. Examples of AmpC -lactamases include CMY, ACT, FOX, MOX, ACC 
and DHA type enzymes76,110. CMY-2 is the most common type detected in companion 
animals, having been identified in dogs from Japan, Denmark and Canada120–122.  
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1.3.3.1.3 Carbapenemases 
The carbapenemase designation most accurately describes a phenotype, which 
includes resistance to the carbapenem antimicrobials (meropenem and imipenem). 
These enzymes are phylogenetically diverse and belong to three different Ambler 
classes including KPC-type (Class A) metallo -lactamase type (Class B) and OXA-48 
type (Class D) enzymes76,110. KPC type carbapenemases have a broad spectrum of 
activity. They hydrolyze penicillins cephalosporins, cephamycins and carbapenems but 
are inhibited by tazobactam and boronic acid76,110. To date a single KPC producing E. 
coli isolate has been identified in a companion animal, originating from a dog suffering 
from recurrent UTIs in Brazil123. Metallo -lactamases are capable of breaking down 
penicillins cephalosporins, cephamycins and carbapenems. However, due to their 
structure, they are susceptible to inhibition by metal chelators such as EDTA. Examples 
of metallo -lactamases include NDM, VIM and IMP type enzymes76,110. To date NDM-1 
and NDM-5 type enzymes have been identified in companion animals. NDM-5 was 
isolated from the feces of a healthy dog in Algeria, while NDM-1 was identified in clinical 
isolates from dogs in China and the U.S.124–126. OXA-48 type enzymes have a 
complicated phenotype exhibiting activity against penicillins, carbapenems and -
lactamase inhibitors but only weakly inhibiting monobactams and ESCs. OXA-48 type 
carbapenemases are inhibited by NaCl110. OXA-48 has been  identified in E. coli of 
companion animal origin in France, Germany, Algeria and the U.S.127–130. 
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1.3.3.2 Fluoroquinolones 
The fluoroquinolones are a broad-spectrum antimicrobial class that exert their 
mechanism of action by interfering with DNA replication49. Originally, acquired 
resistance to fluoroquinolones was thought to occur strictly through chromosomal 
mutation in the genes gyrA and parC that encode the drug target45,131. The first report of 
PMQR originated on an MDR plasmid (pMG252) found incidently in a ciprofloxacin 
resistant urinary isolate of K. pneumoniae in Alabama in 1994132. The protein encoded 
by this gene, (later designated qnrA1), confered reduced susceptibility rather than full 
clinical resistance on its own. However, wild type E. coli to whom pMG250 was 
transferred were 100 times more likely to develop spontaneous mutations when 
exposed in vitro to ciprofloxicin or nalidixic acid132.  
To date, three types of transmissible quinolone resistance genes have been 
reported. The target protecting protein (qnrA, qnrB, qnrC, qnrD and qnrS); the 
inactivating enzyme aac(6′)- Ib-cr, and the efflux pumps qepA and oqxAB45. All of these 
PMQR determinants technically confer reduced susceptibility, indicated by an increase 
in MIC. However, subsequent quinolone (or fluoroquinolone) exposure exerts a selective 
pressure for the acquisition of additional mutations that often result in clinical 
resistance133. The efflux pump oqxAB is an interesting case as it actually has an affinity 
for multiple compounds in addition to (fluoro)quinolones103. This determinant therefore 
provides a mechanism by which reduced susceptibility to multiple classes of 
antimicrobials, including trimethoprim and chloramphenicol, may be co-selected103. A 
variant of an aminoglycoside acetyltransferase enzyme, AAC(6’)IB-CR, that is capable 
of hydrolyzing ciprofloxacin, was first described in 2005134. Currently, the aac(6′)- Ib-cr 
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gene appears to be the most widespread in companion animals, having been identified 
in E. coli from both healthy and diseased animals across Europe, Australia, Asia and the 
U.S.135–139. The tendency of the aac(6′)- Ib-cr gene to co-locate on plasmids harbouring 
ESBLs is of particular concern as it provides the framework for the emergence of MDR. 
These strains have been commonly identified in dogs with UTIs in Asia and Europe135–
138. Many additional PMQR determinants have been detected in dogs in China, Europe, 
Australia and the U.S.136,137,139–143.  
1.3.3.3 Fosfomycin 
Fosfomycin acts by inhibiting UDP N acetyl glucosamine enolpyruvyl transferase 
(MurA), an enzyme required for the first step of peptidoglycan biosynthesis76. In E. coli, 
recognized fosfomycin resistance mechanisms include decreased uptake and enzymatic 
inactivation76,103. Target modification by chromosomal mutations in the murA gene has 
also been described76,103. Specifically, mutations in the hexose phosphate (uhpA and 
uhpT genes) and glycerol 3 phosphate (glpT gene) transporter system involved in 
fosfomycin uptake lead to decreased susceptibility or clinical resistance. Multiple 
fosfomycin-modifying enzymes; including a glutathione transferase (FosA), a thiol 
transferase (FosB) a hydrolase (FosX) and two kinases (FomA and FomB) have also 
been described in E. coli 76,103. Many of the genes encoding these enzymes have been 
identified on plasmids in Gram-negative (fosA) and Gram-positive (fosB) organisms, 
alongside additional resistance determinants144,145. Therefore, fosfomycin resistance can 
be co-selected for in the face of exposure to other antimicrobial agents103. Investigations 
into fosfomycin resistance in companion animals are relatively recent. After the initial 
discover of fosA in dogs and cats in China in 2012 and 2013, fosA has emerged as the 
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most commonly identified fosfomycin resistance mechanism among companion animals 
and appears to be particularly widespread among canine populations in China146–148.  
 
1.4 Antimicrobial resistance surveillance in human urinary tract infections 
The  CDC refers to surveillance as ‘the ongoing systematic collection, analysis, 
and interpretation of data essential to the planning, implementation, and evaluation of 
public health practice, closely integrated with the timely dissemination of these data to 
those who need to know’149. In Canada, national AMR surveillance is under multiple 
initiatives including the Canadian Integrated Program for Antimicrobial Resistance 
Surveillance (CIPARS), and the Canadian Antimicrobial Resistance Surveillance System 
(CARSS). What’s more, coordinated multicentre initiatives for tracking AMR in both 
health care associated, and community acquired UTIs are well established in human 
medicine. The North America Urinary Tract Infection Collaborative Alliance (NAUTICA), 
the Canadian Ward Surveillance Study (CANWARD), the Study for Monitoring 
Antimicrobial Resistance Trends (SMART) and the Meropenem Yearly Susceptibility 
Test Information Collection (MYSTIC) program are several of the prominent programs 
active in North America. 
 
1.4.1 North America 
In Canada, the CANWARD study (initiated in 2007) collects isolates from ten 
participating Canadian hospitals across eight provinces. The most recent resistance 
trends among in and outpatient urinary pathogens collected through the program from 
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2007-2009 indicate that E. coli accounted for 43% and 64% of positive cultures in 
inpatient and outpatient UTI cases respectively150. Overall, among all uropathogens, 
susceptibility rates to nitrofurantoin (96%) and ciprofloxacin (81%) remained high. Over 
the three-year study period for E. coli specifically, statistically significant increases in 
resistance occurred only for amoxicillin-clavulanate and SXT. In addition, 12.2% of E. 
coli were found to be MDR with ciprofloxacin and SXT resistance being over 
represented (95% and 92% respectively) among co-resistant isolates150. In comparison 
to earlier Canadian studies, the prevalence of E. coli resistant to ciprofloxacin has 
increased by more than sixteen times, while nitrofurantoin resistance has increased 
more than twenty fold68,150,151. In contrast, resistance to SXT has remained relatively 
stable over the past decade68,150,151. A summary of the changes in resistance to 
nitrofurantoin, ciprofloxacin and SXT in Canadian urinary E. coli from 1998-2011 is 
summarized in Table 1.568,150,151. SMART reported a similar rate of fluoroquinolone 
susceptibility (71%) among urinary pathogens collected in Canada and the U.S. 
between 2010 and 2014. Suggesting that this trend of decreasing efficacy of 
fluoroquinolones for the treatment of UTIs has continued into the present decade152.  
Additional studies conducted over a ten year period in Canada and the U.S. report 
similar changes in fluoroquinolone resistance from 1.2% to 19.2% and 3% to 17% in 
Canada and the U.S. respectively between 2000 and 2010150,151,153.  
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Table 1.5: Changes in the frequency of nitrofurantoin, ciprofloxacin and SXT resistance 
among urinary E. coli in Canada68,150,151 
 1998 2003-2004 2007-2009 
Nitrofurantoin 0.1% 0% 4.1% 
Ciprofloxacin 1.2% 1.1% 19.5% 
Trimethoprim-
sulfamethoxazole 
18.9% 17.7% 22.1% 
Prevalence of E. 
coli 
84.1% 56.9% 54% 
Total isolates (N) 1681 496 1581 
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In Canada, antimicrobial susceptibility of community acquired urinary E. coli has 
been shown to vary significantly in comparison, to the United States. For example, 
American isolates exhibit significantly higher rates of resistance to ampicillin (39.3% 
versus 33.0%), SXT (22.6% versus 17.7%) nitrofurantoin (1.4% versus 0%), and 
ciprofloxacin (6.8% versus 1.1%)154. This finding was supported by  the more recent 
SMART study (2010-2014) which found that among E. coli collected from 2013-2014, 
resistance to cephalosporins and fluoroquinolones was significantly higher among 
American isolates by about 4% and 6% respectively152. There was also significant 
geographical differences regarding risk of quinolone resistance between regions in the 
U.S. with an approximately 50% increased prevalence among isolates originating from 
the south155. Interestingly, similar variation has also been documented across Canada, 
with the highest rates of multidrug, as well as fluoroquinolone resistance occurring 
among urinary E. coli in British Columbia156,157.  
1.4.2 Global 
The Antimicrobial Resistance Epidemiological Survey on Cystitis (ARESC) is an 
international survey to investigate the prevalence and epidemiology of uropathogens 
causing cystitis worldwide158. Among isolates collected from women with uncomplicated 
cystitis in nine European countries as well as Brazil (2003-2006), E. coli accounted for 
76.7% of isolates. Overall, resistance to SXT (29.4%) and ampicillin (48.3%) were most 
common. Fosfomycin, pivmecillinam and nitrofurantoin were the most efficacious with 
susceptibility rates above 90%158. Among participating countries, resistance to 
ciprofloxacin exceeded 10% in Brazil, Spain Italy and Russia158. In general, the greatest 
geographic variability in susceptibility was observed for SXT (54.5-87.8%) and members 
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of the -lactam family including ampicillin (32.7–65.5%), amoxicillin-clavulanate (51.9– 
93.5%), and cefuroxime (73.0–93.0%)158.  
The European E. coli Sensitivity survey (ECO.SENS) is a longitudinal surveillance 
project focused specifically on tracking the susceptibility of E. coli from female patients 
with uncomplicated cystitis in five European nations159. Most recently, results from 2014 
were compared to susceptibility rates in 2000 and 2008 respectively. Since 2000, there 
has been a significant increase in resistance to the first-generation cephalosporin 
cefadroxil in Germany and Spain, to ciprofloxacin in Germany, Spain, Sweden, and the 
UK, to SXT in Germany, Spain, Sweden, and the UK, to pivmecillinam in Spain, and to 
nitrofurantoin in the UK159. Since 2008, the most astonishing increases in resistance 
have occurred in the UK for ciprofloxacin, SXT and nitrofurantoin159. 
 
1.4.3 Antimicrobial resistance and antimicrobial use  
While the situation in any particular location may vary, some consistent AMR 
trends have been identified among urinary E. coli globally. i) Resistance rates are higher 
among hospital acquired compared to community acquired infections; ii) Resistance to 
oral formulations of fluoroquinolones, -lactams (including aminopenicillins, potentiated 
aminopenicillins and first generation cephalosporins) and SXT commonly used to treat 
UTIs is increasing; iii) Susceptibility to fosfomycin, pivmecillinam and nitrofurantoin 
remain high (>90%) in most regions; and iv) The frequency of MDR is increasing and 
non-susceptibility to fluoroquinolones is over represented among these isolates.  
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Many of these observations appear to have been taken into consideration in the 
most recent modifications to the international UTI treatment guidelines published by the 
IDSA64. In summary, amino penicillins (amoxicillin) and their potentiated counterparts 
(amoxicillin-clavulanate) are no longer recommended for empirical treatment. 
Furthermore, fluoroquinolones are now considered a second line treatment option owing 
to the increasing reports of resistance and their relative importance in treating infections 
other than cystitis64. Current empirical treatment options instead include fosfomycin, 
nitrofurantoin, pivmecillinam and SXT (where regional resistance rates are <20%)64. 
Despite the “international” nature of these guidelines, significant differences in regional 
prescribing practices still exist30. For example, pivmecillinam is largely unavailable in 
North America, but is commonly prescribed in Europe64.  
National treatment guidelines for uncomplicated cystitis in six European countries 
recommend seven different antimicrobials. However, no single drug is consistently 
recommended across all six nations suggesting that regional differences in the 
frequency of resistance affect how guidelines are developed and applied160. For 
example, in Spain, which is a country known for having a significant AMR problem, 
ciprofloxacin resistance rates among urinary E. coli exceeded 20%, yet national 
guidelines continue to recommend fluoroquinolones as first line empirical treatments for 
uncomplicated infections160,161. Interestingly despite its widespread availability and more 
extensive label claims in Europe, the only two European nations currently 
recommending fosfomycin for first line treatment are Spain and Germany160. 
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1.4.4 Molecular epidemiology of resistance in urinary E. coli 
AMU provides the selective pressure for bacteria to develop resistance. The most 
common general mechanisms of AMR include decreased permeability, efflux pumps, 
target protection, target modification, enzymatic inactivation and immunity and bypass. 
Here, an overview of relevant molecular techniques for investigating AMR is provided 
and the epidemiology of resistance genes identified in human urinary E. coli is 
discussed. Special attention is paid to those mechanisms which confer resistance to the 
-lactams and fluoroquinolones which are relevant for treating UTIs.  
1.4.4.1 An overview of molecular microbiology techniques  
The identification of phenotypic AMR, while often considered sufficient for clinical 
purposes, provides an incomplete description of how and why resistance occurs. 
Advances in molecular microbiological techniques in the past decade have allowed for 
more extensive investigations into the mechanism and epidemiology of resistance. Many 
of these techniques are based on polymerase chain reaction (PCR), sequencing, 
restriction digestion, or some combination. PCR is a relatively fast and cheap way to 
identify a gene of interest utilizing short DNA segments (primers) that bind to 
complementary sequences on either end of a specific target. A PCR reaction proceeds 
through many cycles to exponentially amplify the target. At the end, the reaction mixture 
is loaded onto an agarose gel and exposed to an electric field that causes the DNA to 
migrate down the gel. The amplified gene is detected as a band when the gel is imaged 
in the presence of ultraviolet light. PCR methodology can be further exploited to gain 
insight into the genetic relatedness of isolates. For example, multilocus sequence typing 
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(MLST) is a PCR based technique that detects sequence difference in conserved genes 
to determine epidemiological relationships between members of a bacterial species162. 
In short, for each isolate, PCR is carried out on seven conserved housekeeping genes 
and the purified products are sequenced. When the sequence results are compared to 
an MLST database (pubMLST), a distinct allelic profile is assigned to each isolate based 
on the combination of seven unique sequences. From this information each isolate can 
be assigned a sequence type (for example, ST131) which defines a cluster of closely 
related strains. Alternatively, pulse field gel electrophoresis (PFGE) may be used for 
DNA fingerprinting and is an extension of traditional agarose gel electrophoresis. Briefly, 
bacteria from overnight culture is subjected to cell lysis and suspended in plugs of 
agarose gel. Plugs are subjected to restriction digestion by commercially available 
enzymes and loaded into an agarose gel163. A constantly changing electric field is 
applied to separate the resulting large DNA fragments and the gel is stained and imaged 
in the presence of UV light163. The observed banding pattern can be compared to a 
database (PulseNet) of known PFGE profiles, which allows the relationship between 
clinical isolates and reference strains to be determined. These various DNA 
fingerprinting techniques have revolutionized microbiology and allowed for extensive 
digitization and sharing of information for epidemiological purposes. 
1.4.4.2 -lactamases 
-lactamase is a broad term which encompass all enzymes capable of breaking 
down the various antimicrobials belonging to the -lactam class. With respect to 
uropathogenic E. coli, the most problematic -lactamases are those with a broad 
spectrum of activity including ESBLs and AmpC -lactamases76. Interestingly, it is 
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possible for E. coli to possess multiple -lactamase genes which are only detected by 
molecular methods164.  
1.4.4.2.1 Extended spectrum -lactamases 
There are multiple types of ESBLs which including SHV, TEM, and CTX-M types. 
Of these classes, CTX-M type enzymes are particularly prevalent among both hospital 
and community acquired UTIs caused by E. coli 76.  
In North America, the first report of a CTX-M producing urinary E. coli isolate 
occurred in 2002 when 9 clinical isolates (six of which were from the urinary tract) from 
five different states were found to possess these enzymes165. Since their initial 
discovery, screening for ESBLs has become a common part of UTI surveillance studies 
in human medicine. In Canada, rates of CTX-M producing urinary E. coli are relatively 
low. Among 208 E. coli isolates collected from women with uncomplicated cystitis in 167 
towns across Canada, one (0.5%) phenotypic ESBL producer was identified156. Another 
Canadian study investigating ESBL production among E. coli from 11 medical centers 
across Canada identified 209 ESBLs of which 78% were recovered from urine and 62% 
were collected from community acquired infections166. Overall, CTX-M type enzymes 
comprised 82% of ESBLs, of which the majority (71%) were CTX-M-15166. Some of 
these CTX-M-15 producers carried additional -lactamases including those of the TEM 
and OXA types. The remaining 38 isolates possessed various alleles of the SHV and 
TEM type ESBLs166. The SMART study surveying for ESBL production among hospital 
and community acquired urinary E. coli in both Canada and the U.S. identified a 
significant increase in the frequency of ESBLs in the U.S. from 7.8% to 18.3% between 
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2010 and 2014152. In Canada, this increase (10.4% to 13%) did not reach statistical 
significance. However, when just community acquired infections caused by ESBL 
producers was considered, the increase in frequency was significant in both 
countries152. The occurrence of ESBL production among community acquired 
uropathogens was approximately 15% in both countries as of 2015152. Upon further 
molecular characterization of ESBL producers, 90% possessed CTX-M enzymes of 
which the majority were CTX-M-15, followed by CTX-M 14 and CTX-M 27. SHV and 
TEM type enzymes accounted for a minority of isolates (~5%) in both the U.S. and 
Canada152. Interestingly, in this same study, two isolates producing KPC type 
carbapenemases were identified and both originated from the U.S152.  
For global comparison, rates of ESBL production among community acquired 
UTIs in Spain jumped from 7.5% in 2010 to 8.6% in 2012 and this increase was even 
more pronounced for hospital acquired UTIs161. Among urinary E. coli isolates collected 
from a tertiary care hospital in India, 23% were found to harbor ESBLs of which 16% 
produced CTX-M type enzymes167. The most recent results from the ECO.SENS 
initiative identified a phenotypic ESBL frequency of 4.8% among 729 isolates collected 
from five European countries between 2008-2014159. Interestingly, previous results from 
the ECO.SENS study, which characterized ESC resistance in isolates from both high 
AMR burden (Greece and Portugal) and low AMR burden (UK, Austria and Sweden) 
countries found that among 11 (0.6%) ESC resistant isolates, five produced CTX-M 
group 1 and one produced CTX-M group 9 type enzymes168. Interestingly, at this time 
there was at least one ESBL producing isolate identified from each country except 
Portugal168.  
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1.4.4.2.2 AmpC -lactamases 
The prevalence of Amp-C -lactamases is under investigated in Canada. To the 
authors knowledge no studies have specifically investigated the frequency of plasmid 
mediated AmpC -lactamases among urinary E. coli. However, one study identified 232 
cefoxitin (a cephamycin) resistant clinical E. coli isolates from Canadian hospitals, which 
accounted for just 0.8% of the total169. Molecular characterization revealed 25 (11%) 
strains that possessed CMY-2 type AmpC -lactamases169. CMY-2 type plasmid 
mediated AmpC -lactamases have also been reported in the UK, China and the United 
States170–172. 
1.4.4.3 Plasmid mediated quinolone resistance determinants 
The frequency of fluoroquinolone resistance among Enterobacteriaceae has 
increased significantly in the last twenty years45. This observation, coupled with the 
significant association between fluoroquinolone resistance and MDR phenotypes has 
triggered broad scale investigations into the prevalence of the plasmid mediated 
quinolone resistance (PMQR) determinants qnrA, qnrB, qnrC, qnrD qnrS, aac(6′)- Ib-cr, 
and qepA45,155.  
Surveillance for PMQR in Canada is most extensive in the Calgary Health 
Region. An investigation into the occurrence of PMQR among fluoroquinolone resistant 
clinical E. coli isolated from 2004-2007, revealed that the frequency of the aac(6’)-Ib-cr 
gene increased from 4% in 2004 to 13% in 2007173. In 2007, 0.8% of isolates were 
positive for the qnrS gene and one isolate was positive for both genes. All PMQR 
determinants were present in urines and the majority were submitted from community 
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acquired infections173. Interestingly, 13% of isolates co-produced AmpC -lactamases 
and 54% co-produced CTX-M-15 type ESBLs173. In fact, cotransmission of quinolone 
resistance with aminoglycoside inactivating enzymes and ESBLs is quite well document 
and has the potential to facilitate the rapid emergence of MDR174. An additional study 
from the same region investigated the prevalence of PMQR among ESBL producing E. 
coli, 78% of which originated from urine166. Eighty nine percent of these ESBL 
produccers exhibited resistance to ciprofloxacin among which 54% produced the 
aac(6′)- Ib-cr gene and a single isolate produced both the aac(6′)- Ib-cr, and qnrB 
genes166. The final PMQR gene qepA, which encodes an efflux pump, was first reported 
in North America in an E. coli isolate in Canada175. While investigating mechanisms of 
resistance among ESBL producing E. coli isolated in ICU’s across Canada, PMQR 
genes qnr (A, B, and S), qepA, and aac(6′)-Ib-cr were detected in 0%, 5.6%, and 44.4% 
of isolates respectively. Interestingly 100% of isolates also harbored chromosomal 
mutations in the quinolone resistance determining region of gyrA, while 88.9% of 
isolates had mutations in parC175. Unfortunately, the specimen types from which these 
MDR E. coli were isolated was not described.  
Internationally, aac(6′)- Ib-cr is the most widespread of the PMQR 
determinants106. However, qnr genes have also been isolated worldwide, and with the 
exception of qnrS are strongly associated with ESBL production106. Compared to other 
regions, both qnr and aac(6′)- Ib-cr has been isolated with the highest frequency among 
E. coli in North America, Europe and South East Asia176–180. Both qnr and aac(6′)- Ib-cr 
genes were recently described in E. coli isolates in Egypt181. The gene aac(6′)- Ib-cr is 
the only PMQR determinant identified in South America and was identified in an urinary 
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E. coli isolate in Peru in 2005182. QepA is the most recently described PMQR 
determinant and was first identified in an E. coli strain isolated from the urine of a 
hospitalized patient in Japan183. QepA is less commonly associated with ESBL 
production and has been isolated in E. coli in North America, Europe, South East Asia, 
the Middle East and Egypt175,179–181,184. 
1.4.4.4 Clonal spread of uropathogenic E. coli  
The epidemiology of the emergence of AMR among E. coli can generally be 
described as clonal or non-clonal in nature. The former refers to the propagation of a 
single resistant clone by the vertical transmission of resistance genes from parent 
bacteria to their offspring. Clonal spread is likely in a genetically homogenous 
population. These isolates cluster closely together when their relatedness is investigated 
by molecular techniques such as PFGE or MLST. In contrast, non-clonal spread occurs 
by the horizontal transmission of resistance determinants within an otherwise unrelated 
(heterogenous) population. This type of spread is facilitated by the presence of mobile 
genetic elements such as plasmids. Both epidemiological processes have been 
described in uropathogenic E. coli. However, the clonal spread of MDR strains has 
implications in community outbreak scenarios for interrupting transmission and reducing 
selective pressure for resistance185. This section will discuss four examples of MDR 
urinary E. coli clones identified in outbreak scenarios around the world186,187. 
1.4.4.4.1 E. coli O15:K52:H1 
E. coli clonal group O15:K52:H1 was originally identified in South London during 
a twelve-month outbreak of community acquired UTIs between 1986-1987. In three 
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cases septicemia and additional infectious syndromes were identified and three patients 
died188. All isolates exhibited identical resistance phenotypes to ampicillin, streptomycin, 
tetracycline, sulfamethoxazole, trimethoprim and chloramphenicol. As a result, a local 
London hospital carried out screening of all blood and urine that was culture positive for 
E. coli between November 1986 and January 1988189. Of 25 urinary E. coli identified as 
O15, 80% expressed this resistance profile and 17 of these were temporally clustered in 
a four-month period. The proportion of serogroup O15 isolates fell gradually until, in 
June 1988, only 4.2% of urinary E. coli isolates belonged to this group189. Though this 
outbreak clustered together in time and space, additional investigations in Spain and 
North America indicate that this particular clone is widespread geographically. Despite 
possessing more diverse resistance profiles in these regions, members of this lineage 
retain a conserved and highly pathogenic virulence profile190,191. In fact, a more recent 
investigation of 199 E. coli isolates causing community acquired  UTIs in Canada 
suggests that E. coli O15K2:H1 has re-emerged in Canada with a similar virulence 
profile and a recently acquired fluoroquinolone resistance phenotype186.   
1.4.4.4.2 E. coli O78:H10 
 A distinct strain, designated O78:H10, was found to be responsible for a more 
contained 1991 outbreak of community acquired UTIs in the greater Copenhagen 
area192. All isolates were lactose non fermenters and possessed identical phenotypes 
that included resistance to ampicillin, chloramphenicol, streptomycin, sulphonamides, 
tetracyclines and trimethoprim. Twenty six percent of isolates examined over an eight-
month period had an identical phenotype and belonged to the O78:H10 serotype192. All 
but one isolate originated from the urinary tract and 74% were community acquired. 
 - 50 - 
Previous antibiotic exposure was a common risk factor among affected patients192. The 
clustering of this serotype in time and space points to the potential value of using 
phenotypic data as an initial screen to identify closely related MDR uropathogens by 
serotyping or more advanced molecular methods (PFGE, MLST).   
1.4.4.4.3 Clonal Group A 
A significant increase in the prevalence of SXT resistance among community 
acquired urinary E. coli in the late 1990s prompted multiple investigation into the 
epidemiological relationship of these isolates in the United States193. A single clonal 
group designated clonal group A (CGA) accounted for between 38% and 55% of SXT 
resistant community acquired UTIs in three geographically distinct communities across 
the U.S.193. In fact, during a four-month period, CGA accounted for roughly 9 and 11% of 
all UTIs in Minnesota and California respectively. What’s more, CGA isolates were 
significantly more likely to exhibit MDR compared to non-CGA isolates193. Additional 
investigations in Colorado and multiple centers across the country found that CGA 
accounted for between 34% and 43% of SXT resistant UTIs in a similar time 
period194,195. What’s more, molecular DNA fingerprinting and analysis of virulence 
factors found a highly conserved PFGE profile and virulence genotype among CGA 
isolates causing both pyelonephritis and cystitis across a vast geographical area194. It is 
likely that the clonal spread of this group made a significant contribution to the rapid 
emergence of SXT resistance observed in the U.S. at the beginning of the 21st century. 
More recently CGA has been identified among SXT resistant isolates in Montreal and, to 
a lesser extent, in the Calgary Health Region of Western Canada186,196.  
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1.4.4.4.4 E. coli O25:H4:ST131 
The most recent, widespread and extensively studied clonal group tied to 
community acquired uropathogenic E. coli was originally identified in the Northwest of 
England197. Members of the lineage ST131 (identified by MLST) were over represented 
(accounting for 59%) among uropathogens isolated in this region. What’s more 98% of 
isolates belonging to ST131 were also found to be phenotypically resistant to ESCs197. 
Since it’s identification, MDR urinary E. coli of the ST131 lineage (known more 
specifically as E. coli O25:H4:ST131), have been identified in India, Japan, Kuwait, 
Lebanon, Korea, Canada, the United States, Switzerland, France, Portugal, Spain, 
Croatia, the UK, Norway and Turkey167,176,185,198–204.  
Isolates belonging to ST131 tend to possess the ESBL allele CTX-M-15, are 
commonly fluoroquinolone resistance and are particularly pathogenic with respect to 
their virulence profile. Investigations into the virulence potential, AMR and 
epidemiological relatedness of ESBL and non ESBL producing E. coli in the U.S. found 
that the majority of isolates possessing ESBLs produced CTX-M 15 (58%) and that 
possession of CTX-M 15 was significantly associated with both fluoroquinolone 
resistance and ST131 membership185. Interestingly, even among isolates that did not 
produce ESBLs, members of ST131 were still significantly more likely to be 
fluoroquinolone resistant185. In the same study, the overall prevalence of ST131 was 
16%, with isolates of this sequence type accounting for 67%–69% of ESC or 
fluoroquinolone resistant isolates, 55% of fluoroquinolones and SXT resistant isolates 
and 52% of MDR isolates185. ST131 E. coli also possess more diverse virulence profiles 
when compared with other resistant isolates185. Overall, members of this pandemic 
 - 52 - 
lineage possess a unique combination of pathogenicity and MDR, with a high likelihood 
of both fluoroquinolone and/or ESC resistance185. A Canadian study investigated the 
prevalence of ST131 among ESBL producing E. coli collected from 11 different medical 
centers of which 78% were from UTIs and 62% were from community acquired 
infections166. Similar to the situation in the U.S., The majority of ESBLs identified were of 
the CTX-M type and CTX-M-15 (70%) was most common, though it ranged in frequency 
from 37% in British Columbia to 95% in Ontario166. ST131 comprised 46% of the 
population of ESBL producers, though this lineage ranged in prevalence across Canada 
from 21% in BC to 65% in Ontario166. The majority of ST131 E. coli (91%) produced 
CTX-M-15 and 69% were positive for the PMQR determinant aac(6’)-Ib-cr166. Still 
another study investigated the prevalence of ST131 in urinary E. coli stratified for 
fluoroquinolone susceptibility. ST131 was overrepresented among fluoroquinolone 
resistant isolates, accounted for nearly half of the fluoroquinolone resistant 
population186. Interestingly, all but one ST131 isolate was susceptible to third generation 
cephalosporins and none possessed CTX-M-15186. The detection of fluoroquinolone 
resistant ST131 strains without CTX-M enzymes suggests that although this strain 
initially rose to prominence due to its association with CTX-M production, it is first and 
foremost a fluoroquinolone resistance pathogen that subsequently developed ESC 
resistance through the acquisition of CTX-M type enzymes. Thus, there is the potential 
for the future dissemination of CTX-M 15 within members of ST131 if frequent 
fluoroquinolone use continues in the treatment of uncomplicated cystitis across Canada. 
E. coli ST131 is a globally prevalent, MDR and particularly pathogenic cause of 
community acquired UTIs that appears to have disseminated by clonal spread in the 
early 21st century.  
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1.5 Antimicrobial resistance surveillance in canine urinary tract infections  
1.5.1 Canadian Surveillance 
Few studies have investigated the prevalence of resistance in canine urinary E. 
coli in Canada. Susceptibility results from canine urinary isolates submitted  to a regional 
diagnostic laboratory in Western Canada were analyzed retrospectively205. This study 
included both non recurrent and recurrent infections, defined as more than one positive 
culture from the same patient during the study period. The panel of antimicrobials tested 
included ten drugs belonging to seven different classes205. E. coli was most frequently 
isolated (44.1%) followed by Staphylococcus spp (11.6%). Though resistance rates 
were not explicitly stated on a drug by drug basis, the authors found a significant 
increase in the number of antimicrobials to which recurrent E. coli were resistant over 
the study period205. In addition to being out of date, limitations of this study include the 
purely phenotypic nature of the results, and the employment of disk diffusion-based 
susceptibility testing. The use of molecular techniques could reveal Information about 
the mechanism and nature of resistance (chromosomal versus transmissible), while also 
identifying the emergence of globally prevalent resistance genes and strains. For 
example, E. coli producing CTX-M type ESBLs or strains belonging to ST131. The only 
study employing molecular techniques to investigate the prevalence and mechanisms of 
resistance in canine urinary E. coli in Western Canada revealed a remarkably 
susceptible population with 80% of isolates exhibiting pan susceptibility to all 
antimicrobials tested122. Reduced susceptibility to ampicillin (8.8%), and extremely low 
levels of quinolone resistance were identified with just 7% of isolates exhibiting 
resistance to nalidixic acid and <2% displaying ciprofloxacin resistance122. A single 
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CMY-2 type AmpC -lactamase was identified122. Additional surveillance studies 
investigating resistance among canine uropathogens in Canada are needed to both 
inform prescribing practices and provide a baseline for future surveillance.  
1.5.2 International Surveillance 
Surveillance efforts for canine uropathogens are occurring on various scales 
across the globe. Often urinary E. coli are included as part of a larger investigation with 
respect to the infection site, host (most often canine and feline) and pathogens (E. coli 
among other Gram-positive and negative pathogens) included. This section summarizes 
the surveillance literature that exists for canine urinary E. coli around the world. 
1.5.2.1 North America 
In the United States pathogenic E. coli isolated from companion animals have 
been more extensively studied compared to Canada. Most studies have indiscriminately 
investigated clinical E. coli isolates from all extra-intestinal infection sites206–208 in both 
cats and dogs207,208. These investigations indicate that most isolates are from canine 
infections (75-80%) with the majority obtained from the urinary tract (58-71%)206–208. 
Though the antimicrobial panels tested are not consistent across these studies, 
tetracyclines and -lactams were the most common classes to which isolates were 
reported as resistant, especially the aminopenicillins amoxicillin and ampicillin (30-
60%)206–209. In general, susceptibility to fluoroquinolones and aminoglycosides remained 
high (>80%) among pathogenic E. coli206–208. However, fluoroquinolone resistance was 
significantly associated with MDR in multiple investigations207,208. Though the definitions 
varied between studies, reported rates of MDR ranged from 21-52%207–209. One study 
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reported lower rates of MDR among urinary E. coli compared to E. coli isolated from 
non-urinary extra intestinal sites208.  
A single study focused exclusively on the susceptibility of canine uropathogens to 
commonly prescribed antimicrobials over a three-year period209. Among both 
uncomplicated and complicated infections, E. coli was the most frequently identified 
pathogen (52%). E. coli isolated from complicated UTIs were significantly more likely to 
be resistant to amoxicillin-clavulanate, ampicillin, chloramphenicol, doxycycline, 
enrofloxacin, ticarcillin-clavulanate and SXT when compared to uncomplicated UTIs209. 
The results of this and other longitudinal investigations suggest that, with the exception 
of tetracycline resistance, which increased significantly according to one study207 the 
susceptibility of canine pathogenic E. coli to commonly prescribed oral antimicrobials 
remained stable over time206,208,209.    
1.5.2.2 South America 
South America represents a significant gap in our knowledge of resistance 
among canine urinary pathogens. In a single study of Brazilian isolates, AMR and 
virulence was investigated among 43 E. coli isolated from both dogs (n=36) and cats 
(n=7)210. Of the agents tested, the frequency of resistance was highest to tetracycline 
(36%), ampicillin (37%), aminoglycosides (40%), and SXT (40%). Interestingly, all 
fluoroquinolone resistant isolates (16%) were also MDR and resistance to third 
generation cephalosporins was less than 5%210. Roughly half of the isolates were MDR 
to three or more antimicrobial classes. In general, resistance in this region is high with 
 - 56 - 
less than 90% susceptibility reported to all antimicrobial classes with the exception of 
third generation cephalosporins and chloramphenicol210.   
1.5.2.3 Europe 
Globally, Europe claims the most extensive literature investigating AMR among 
canine urinary E. coli. As of February 2018, a review of the literature reveals eleven 
investigations originating from nations that include Denmark, the Netherlands, Poland, 
Portugal, Sweden (n=2), Switzerland (n=2) and the United Kingdom (n=3). Regulations 
surrounding AMU in veterinary medicine are perhaps most progressive in Northern 
European countries such as Sweden and Norway where both AMR and AMU in 
companion animals are reported nationally1. Two Swedish studies conducted in 2005 
and 2014, report relatively stable rates of AMR among canine urinary E. coli 211,212. 
However, one investigation reported a more than 5% reduction in the prevalence of 
resistance to ampicillin and tetracycline when they compared urinary E. coli isolates 
collected in the periods 1991-1993 to those collected from 2002-2003211. Levels of 
resistance to all other antimicrobials remained stable over the ten year study period211. 
The more recent 2014 study reported similar results, including pan susceptibility rates of 
79% among canine urinary E. coli isolated in Sweden between March and December 
2009212. Reduced susceptibility was identified to ampicillin (87.9%) and amoxicillin-
clavulanate (87.2%) and rates of MDR were astonishingly low at just 4%212. Studies 
originating out of Denmark and Poland investigated AMR among both canine and feline 
diagnostic E. coli isolates213,214. Compared to Sweden, Danish isolates were only slightly 
more resistant to common antimicrobials. Among 53 urinary E. coli isolates, the 
frequency of resistance was less than 20% across all agents tested with resistance to 
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sulfonamides (19.2%), tetracycline (19.2%) and ampicillin (15.4%) being reported most 
commonly214. In contrast, the frequency of resistance among canine diagnostic E. coli 
isolates in Poland was much higher. Though just 16.7% of isolates originated from the 
urinary tract, resistance exceeded 20% for all thirteen antimicrobials tested, including an 
alarming rate  of amoxicillin resistance (~70%)213.  Three studies have more specifically 
investigated -lactamase production among urinary E. coli in Portugal, the Netherlands 
and Switzerland respectively29,215,216. High levels of resistance to first line drugs, 
including aminopenicillins, first generation cephalosporins and potentiated 
aminopenicillins were reported across all three studies. However, these isolates remain 
remarkably susceptible (>90%) to third generation cephalosporins29,215,216. In 
Switzerland, the frequency of AMR remained relatively stable over the ten-year period 
from 2003-2013. Among pathogenic E. coli isolated from companion animals, resistance 
rates of less than 10% were reported across all antimicrobials tested in one 2003 
study217. Similarly in 2013, the majority of 107 urinary E. coli in Switzerland displayed 
pan susceptibility across all antimicrobials tested216. The most recent surveillance study 
out of the United Kingdom captured resistance among canine urinary isolates over a ten 
year period from 1999-2009 and concluded that there was no significant difference in 
the number of antimicrobials to which urinary E. coli were resistant over the study 
period218. Older longitudinal studies conducted in the UK from 1989 to 1997 included 
pathogenic canine E. coli isolated from dogs in community practice and hospital 
environments219,220. According to the authors, statistically significant changes in 
resistance were restricted to the -lactams amoxicillin, and amoxicillin-clavulanate over 
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this time period, suggesting that rates of AMR have remained stable over the last 
decade219,220.  
1.5.2.4 Asia 
In Asia, longitudinal UTI surveillance studies have been published from Japan, 
Iran and Taiwan221–223. While two of these studies focus exclusively on canine infections, 
including investigations into molecular mechanisms, the study out of Japan included 
strictly a phenotypic description of resistance among canine and feline pathogenic E. 
coli, isolated from both urinary and genital sites. However, the majority (63.4%) of 
isolates were obtained from canine UTIs222. Considering the geographic diversity of Asia 
including the isolated nature of Japan and Taiwan, it is perhaps not surprising that rates 
of resistance reported from these regions differ considerably. In Taiwan, the frequency 
of resistance was highest to oxytetracycline (60.5%) ampicillin (50%), amoxicillin 
(44.7%), nalidixic acid (38.6%), SXT (34.2%), chloramphenicol (31.6%) and doxycycline 
(28.9%) and ~50% of isolates exhibited MDR. The vast majority of isolates remained 
susceptible to  the fluoroquinolones, aminoglycosides and amoxicillin-clavulanate with 
<10% resistance detected223. In Japan, resistance to at least one antimicrobial was 
reported in 62.5% of isolates and resistance to ampicillin (53%) and enrofloxacin (46%) 
was most prevalent. Approximately 53% of canine isolates were MDR and a single 
isolate obtained from a dog was pan resistant to all nine agents tested222. In Iran, urinary 
E. coli isolates were collected from healthy patients and those diagnosed clinically with 
UTIs. Overall, the highest rates of resistance were reported for gentamicin (95%), 
ampicillin (85%), amikacin (70%), amoxicillin (65%), and SXT (65%). Alarmingly, 100% 
of E. coli isolated from apparently health dogs harbored resistance to at least one 
 - 59 - 
antimicrobial, while isolates from infected dogs demonstrated resistance to at least two 
agents221.   
1.5.2.5 Africa 
Information regarding the prevalence of resistance among canine uropathogens 
on the African continent is limited. A single investigation conducted in South Africa in 
2017 determined the susceptibility of canine urinary E. coli to fifteen drugs224. Alarming 
rates of resistance ranging from 65-100% were reported against penicillin, amoxicillin, 
cephalothin and doxycycline224. While still higher than most other regions, the frequency 
of resistance was much lower for enrofloxacin (16.7%) and orbifloxacin (21%), 
chloramphenicol (24.6%) and SXT (24.7%)224. None of the antimicrobial tested were 
more than 90% efficacious in vitro. What’s more MDR, defined as resistance to at least 
one drug in more than three antimicrobial categories, was astonishingly common 
occurring in 98% of isolates224.  
1.5.2.6 Australia and New Zealand 
Despite their relatively close proximity, canine urinary E. coli in Australia and New 
Zealand vary in their susceptibility to commonly prescribed antimicrobials. In New 
Zealand, a longitudinal study which took place from 2005-2012 reported significant 
increases in resistance to amoxicillin-clavulanate, cephalothin and enrofloxacin225. 
However, the frequency of resistance to clinically relevant antimicrobials remained 
below 10% for all agents with the exception of cephalothin (21.9%) in 2012225.  
In Australia, two studies have investigated pathogenic E. coli from canine and 
feline infections21,226. Among 883 E. coli, including 58.2% isolated from dogs, 61.3% 
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were pan susceptible to all antimicrobials tested. Among canine urinary E. coli 
specifically, resistance to -lactams was most common, including cephalothin (95.4%), 
amoxicillin-clavulanate (28.6%) and ampicillin (26.8%)226. Susceptibility to 
fluoroquinolones, aminoglycosides and third generation cephalosporins was comparably 
high, while resistance to the carbapenem imipenem was not detected226. Older 
Australian data obtained in a case series investigating MDR extra-intestinal E. coli 
isolated from 37 dogs, found that all but one UTI resolved after treatment with 
amoxicillin-clavulanate or chloramphenicol21. These findings suggest that resistance to 
commonly prescribed antimicrobials, especially the -lactam class, have increased 
substantially in Australia over the past decade.  
In general, AMR among canine urinary E. coli across Europe (with the exception 
of Poland) and New Zealand have remained relatively low compared to other regions 
and are perhaps most comparable to those obtained in Canadian studies. On a global 
scale, relatively more European nations play host to long standing national surveillance 
programs, that include companion animal pathogens. The longitudinal nature of these 
efforts is particularly valuable for providing a reference to which the emergence of AMR 
in veterinary pathogens may be compared. In contrast, the frequency of resistance 
among canine urinary E. coli in Poland, Brazil, Asia and Africa is high compared to other 
regions and the prevalence of MDR is particularly alarming in these areas213,222–224.  
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1.6 Antimicrobial resistance surveillance in veterinary medicine 
Tracking the emergence and spread of AMR in veterinary pathogens is just one 
part of a complex surveillance system that considers both AMU and resistance in 
multiple host (human and veterinary) and microbial (commensal, clinical, zoonotic) 
populations. As of 2019, twenty countries currently play host to national surveillance 
systems that encompass AMU and/or AMR in veterinary medicine and these initiatives 
cover the Americas, Europe, Asia and Australia1.  A summary of the scope of these 
programs is summarized in Table 1.61.  The resistance trends in human and (to a much 
lesser extent) canine urinary pathogens outlined thus far provide an excellent starting 
point for discussing the strengths and limitations of current and future surveillance 
initiatives in companion animal veterinary medicine.
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Table 1.6: National AMR surveillance systems encompassing veterinary pathogens1 
Program Country Status Type Scope Sampling Type Organisms Funding 
The Americas 
CIPARS227 Canada Established 
2002 
AMU and 
AMR 
Food animals, 
humans, food 
AMR- clinical 
isolates from 
humans, isolates 
collected 
throughout food 
chain from 
animals, 
slaughterhouses 
and retail sources 
Salmonella 
Campylobacter 
E. coli 
Public health 
agency of 
Canada 
NARMS228 United States Established 
1996 
AMR Food animals, 
humans, food 
AMR- public health 
laboratories 
Salmonella 
Shigella 
E. coli 0157 
Vibrio 
Campylobacter 
FDA, USDA, 
CDC 
COIPARS229 Colombia  AMR Food animals, 
food 
AMR- poultry 
throughout food 
chain 
Salmonella PHAC, Instituto 
Colombiano 
Agropecuario, 
WHO, Pan 
American Health 
Organization 
Europe 
CODA-CERVA 
(Now 
SCIENSANO)230 
Belgium Veterinary 
monitoring 
established 
2001 
AMR Food animals AMR- On farm, 
healthy animals at 
slaughter  
Salmonella,  
MRSA  
Enterococcus,  
E. coli  
Federal public 
service for public 
health, food chain 
safety and 
environment  
DANMAP36 Denmark Established 
1995 
AMU and 
AMR 
Food animals, 
companion 
animals, 
humans, food 
AMU- pharmacies, 
veterinarians and 
feed mills 
AMR- Healthy 
production animals 
at slaughter,  
Salmonella, 
Campylobacter 
Clostridium difficile 
Enterococcus,  
E. coli,  
ESBL producing 
Enterobacteriaceae 
Ministry of health, 
ministry of 
science, 
innovation and 
higher education, 
ministry of food, 
agriculture and 
fisheries 
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FINRES-Vet37 Finland Established 
2002 
AMU and 
AMR 
Food animals AMU- drug 
wholesalers 
AMR- clinical 
isolates and 
healthy animals at 
slaughter 
Salmonella 
Campylobacter  
Enterococcus  
E. coli 
Government 
agency 
RESAPATH38 France Established 
1982 
AMU and 
AMR 
Food animals, 
companion 
animals, 
humans  
AMU- sales data, 
all veterinary use 
AMR- Laboratory 
antibiogram data 
from diseased food 
and companion 
animals   
Salmonella 
Campylobacter 
Clostridium difficile 
Enterococcus  
E. coli 
Ministry of 
agriculture 
BfT GERM-VET 
GERMAP231 
Germany Established 
2001 
AMU and 
AMR 
Food animals, 
companion 
animals, 
humans 
AMU- Sales data 
AMR- clinical data 
from laboratories 
Range of organisms Federal office of 
consumer 
protection and 
food safety,  
Hungarian 
National 
System232 
Hungary Established 
2001 
AMR Food animals AMR- colon 
samples of food 
animals at 
slaughter 
E. coli 
Salmonella 
Campylobacter 
Enterococcus 
Ministry of 
Agriculture 
ITAVARM233 Italy  AMU and 
AMR 
Food animal, 
companion 
animals 
AMU- all veterinary 
use 
AMR- clinical 
isolates, health 
animals at 
slaughter 
Salmonella 
E. coli 
Enterococcus 
Pasteurella 
Staphylococci 
Streptococci 
Brachyspira 
hyodysenteriae 
Government 
program 
MARAN234 Netherlands  AMU and 
AMR 
Food animals AMU- drug sales 
from Dutch 
veterinary 
pharmaceutical 
industry 
AMR- Healthy 
animals at 
slaughter 
 
Salmonella 
Campylobacter  
Enterococcus  
E. coli 
MRSA 
Central veterinary 
institute within 
food and 
consumer 
product safety 
authority 
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NORM VET39 Norway Established 
2000 
AMU and 
AMR 
Food animals, 
companion 
animals, 
coordinates 
with human 
program 
(NORM) 
AMU- drug 
wholesalers and 
feed mills 
AMR- active and 
passive laboratory 
data 
Salmonella 
MRSA 
E. coli  
Norwegian 
zoonosis centre 
at Norwegian 
Veterinary 
Institute 
VAV Network 
(VISAVET)235 
Spain Established 
1997 
AMR Food animals, 
companion 
animals  
AMR- Zoonotic 
and commensal 
bacteria from 
slaughterhouses 
 
Pathogens from 
diagnostic 
laboratories 
Healthy animals 
E. coli  
Enterococcus 
Salmonella 
Campylobacter 
 
Diseased 
S. aureus 
E. coli  
Enterococcus 
 
Food animals 
E. coli  
Enterococcus 
Salmonella 
Campylobacter 
Ministry of 
environment, 
rural and marine 
affairs 
SVARM40 Sweden 1992 AMU and 
AMR 
Food animals, 
companion 
animals, 
coordinates 
with human 
program 
SWEDRES 
AMU- Pharmacy 
data 
AMR- active and 
passive laboratory 
data 
Enterococcus  
E. coli  
Various zoonotic 
National 
veterinary 
institute Sweden 
ARCH-VET236 Switzerland Established 
2002 
AMU and 
AMR 
Food animals, 
coordinates 
with human 
program 
ANRESIS 
AMU- sales data 
AMR- Clinical 
isolates and 
healthy animals at 
slaughter 
Salmonella 
Campylobacter  
MRSA 
Enterococcus  
E. coli 
ESBL producing 
Enterobacteriaceae 
 
 
 
Government 
agency 
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UK-VARSS237/ 
SAVSNET41 
United 
Kingdom 
 AMU and 
AMR 
Food animals, 
companion 
animals, 
AMU- sales data, 
survey data of 
prescribing 
practices 
AMR- clinical 
isolates, laboratory 
data  
Campylobacter  
E. coli 
25 species in total 
 
Government 
agency under 
veterinary 
medicines 
directorate, 
British Small 
Animal Veterinary 
Association, 
University of 
Liverpool 
Asia 
Domestic and 
veterinary use 
and drug 
residues in 
products of 
animal origin 
database 
retrieval 
system238 
China  AMU and 
residues 
Antimicrobials 
for veterinary 
use 
AMU- active 
ingredient, type of 
disease, type of 
animal 
N/A Government 
program 
NAMP239 Korea Established 
2009 
AMR Veterinary 
species, 
humans 
Not specified Not specified Government 
program 
JVARM240 Japan Established 
1999 
AMU and 
AMR 
Food animals AMU- sales data, 
all veterinary use 
AMR- clinical 
laboratory isolates 
and healthy 
animals on farm 
Salmonella 
Campylobacter  
Enterococcus  
E. coli 
Actinobacillus 
pleuropneumoniae 
Pasteurella 
multocida 
Streptococci 
Mannheimia 
Haemolytica 
Ministry of 
Agriculture, 
Forestry and 
Fisheries 
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CIPARS, Canada’s National surveillance program, has been in place since 2002 
and monitors both AMU and AMR in animals, humans and food. Upon closer inspection 
of the scope of this program, it becomes evident that resistance in veterinary pathogens 
of companion animal origin is not currently captured within the CIPARS framework227. In 
general, the utility of surveillance data is only as strong as the program used to obtain it. 
Key components in the development of a surveillance system include consideration for 
the program type, geographic range, program scope, specimen types and sampling 
programs, laboratory procedures and logistical issues such as the basis of participation, 
data reporting and funding/governance1. These factors provide the framework for 
discussing what a high-quality, disease specific AMR surveillance program for 
companion animal urinary pathogens might look like in Canada.  
1.6.1 Program type 
National surveillance systems vary substantially in their nature. Specifically, 
whether AMU and AMR are monitored in isolation or in an integrated fashion. For 
example, while countries like Denmark monitor AMU (VetStat) and AMR (DANMAP) 
under separate initiatives, France captures both under a single program (RESAPATH). 
Still other countries monitor only AMU (China) or AMR (Australia, U.S., Colombia, 
Belgium, Hungary, Spain and Korea). Variations in program type are often reflective of 
infrastructural differences between countries. For example, in Canada, CIPARS is able 
to track the wholesale of drugs sold for use in animals, however, they are unable to 
report more specifically on veterinary AMU as there is no centralized body for 
mandatory reporting1,30,242. Furthermore, Canadian veterinarians’ practice of both 
prescribing and dispensing antimicrobials at the individual practice level, at times 
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prescribing generic formulations from human pharmacies, or use of antimicrobials in an 
extra label manner, makes this information particularly difficult to capture in surveillance 
programs242. This is in contrast to European nations like Sweden and Denmark, where 
all veterinary AMU is by prescription only and is therefore nationally reported1,242. An 
ideal and truly epidemiology-based system would successfully track and integrate 
information regarding general and disease specific AMU and resistance in humans, 
animals and environmental sources including food.  
1.6.2 Geographic range 
Surveillance systems vary from local to global in their geographic range. For 
example, the Global Antimicrobial Resistance Surveillance System (GLASS) launched 
by WHO in 2015 seeks to develop a standardised approach to the collection, 
processing and sharing of AMR surveillance data across the globe243. While global 
surveillance efforts are informative for making comparisons between regions, local or 
institution specific data is required for informing prescribing practices244. For example, 
the geographic extent and diversity of Canada necessitates the implementation of 
regional programs to establish local estimates of AMU and AMR in veterinary 
pathogens1. Such programs provide invaluable epidemiological information to advise 
local AMU and to describe the emergence of AMR50. In fact, as discussed within the 
context of human urinary pathogens, there is strong evidence for significant geographic 
variability in resistance, further supporting the need for region specific surveillance 
efforts in Canada30,68,245. 
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1.6.3 Program scope 
Program scope generally refers to the hosts (healthy or diseased companion 
animals, food animals, humans, food), bacteria (zoonotic, commensal, pathogenic) and 
antimicrobial agents included in a surveillance system1. In fact, the scope of a 
surveillance program is greatly influenced by regional differences in production systems, 
disease pressure, resources for disease control and prevention and access to 
antimicrobials242. For example, as a developed nation with relatively low disease 
pressure and access to diagnostic resources, CIPARS tracks resistance in healthy 
animals, diseased animals, diseased humans and retail food sources including beef and 
chicken. However, the scope of this program is largely geared towards identifying 
human health hazards such that the only veterinary species monitored are production 
animals raised for human consumption including poultry (chickens and turkeys), pigs, 
beef cattle, and to some extent, horses. Companion animals, on the other hand, are not 
included1. This is in contrast to European nations, including France, Germany, Italy, 
Norway, Spain, and Sweden who monitor AMR in clinical isolates from companion 
animals1.  
With respect to bacterial species, CIPARS monitors commensal and pathogenic 
enteric organisms from food animals with the potential for food borne transmission 
including227: 
• Salmonella spp: Clinical isolates from humans, horses, turkeys, chickens, pigs 
and beef cattle, abattoir samples from chickens and pigs, on farm samples from 
beef cattle, chickens, turkeys and pigs, retail chicken and turkey samples 
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• Campylobacter spp.: Abattoir samples from beef cattle, chickens and pigs, on 
farm samples from beef cattle, chickens and turkeys, retail chicken and turkey 
samples 
• E. coli: Abattoir samples from beef cattle chickens and pigs, on farm samples 
from beef cattle, chickens, turkeys and pigs, retail chicken, turkey and beef 
samples 
While this restricted scope is not surprising considering a major objective of CIPARS is  
to assess the public health impact of AMU and AMR in humans and animals, veterinary 
guidelines identify canine UTIs caused by E. coli and skin infections caused by 
Staphylococcus spp. as important targets worthy of surveillance49. Because these 
companion animal pathogens are not addressed by CIPARS, monitoring their 
susceptibility relies on regional investigations if information about the prevalence of 
resistance to clinically important antimicrobials is to be obtained49.  
A common criticism of CIPARS is its lack of clearly articulated goals or targets for 
success242. This is a common issue with surveillance studies as most often they are 
descriptive in nature, successfully identifying phenotypic resistance but failing to provide 
a molecular explanation or a practical context within which the results can be 
interoperated or applied. In fact, there is emerging evidence in human medicine that 
AMR surveillance has a role to play in disease based antimicrobial stewardship 
programs246.  For example, with respect to reducing AMU and improving management 
of asymptomatic bacteriuria and UTIs, a combination of guideline implementation and 
education on local uropathogen resistance rates improved prescribing patterns and 
management of these infections in multiple clinical settings246. In a reciprocal manner, 
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surveillance initiatives could use guidelines published by organizations like the IDSA, or 
ISCAID to provide scope and focus for surveillance with respect to defining pathogens 
and antimicrobials of clinical interest. Clearly defined objectives, whether they be to 
establish a baseline for future surveillance studies (phenotypic), to detect the 
emergence of resistance in a region (molecular) or to inform treatment decisions 
(phenotypic in the context of clinical guidelines) drastically change the inclusion criteria 
and scope of surveillance studies.  
1.6.4 Specimen type and sampling procedures 
Data collection in surveillance systems can be active; involving the application of 
some systematic search tool to identify cases, or passive; based on voluntary or routine 
reporting systems149. In both cases, selection and sampling bias are imbedded in the 
nature of surveillance studies. With respect to AMR, passive, or convenience sampling, 
can either involve laboratory isolates or laboratory susceptibility data242. In most cases 
these studies are also retrospective in nature such that the amount of clinical data, 
including patient demographics, case definitions and clinical outcomes is limited242. For 
example, regarding sampling procedures for Salmonella; CIPARS’ reliance on passively 
acquired laboratory isolates resulted in significant sampling bias such that greater than 
70% of their isolates originated from a single province over one year242. The Danish 
national surveillance program DANMAP, on the other hand, used a form of 
“pseudorandom” selection of isolates from three different national centers for their 
Salmonella surveillance242. In the case of urinary isolates, resistance patterns captured 
by laboratory susceptibility data most accurately reflect complicated or recurrent UTIs 
since empirical treatment is common and culture is unusual unless initial treatment has 
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failed50. In general, both sampling and selection bias can be mitigated by increasing the 
amount of epidemiological data collected per isolate, as occurs most often in 
prospective studies242. What’s more the application of strict inclusion criteria regarding 
specimen type, and method of collection, for example, further mitigate the inherent 
biases that often plague surveillance data.  
1.6.5 Laboratory procedures 
Laboratory procedures regarding testing and interpretation are inconsistent 
across the surveillance literature and are often based on the standard protocols of the 
submitting laboratory rather than a programmatic standard. Definitions of susceptible, 
intermediate and resistant used to interoperate susceptibility results are highly variable 
across the literature, with the intermediate category inconsistently categorized into one 
of the other groups. While standardized quality control strains and interoperative 
breakpoints exist, they vary according to region; European Committee on Antimicrobial 
Susceptibility testing, (EUCAST) versus CLSI, host; human versus veterinary and 
infection site; urine, versus blood or bladder, for example. What’s more definitions of 
MDR; a very commonly reported parameter in microbiology, varies based on different 
interpretations of what constitutes an antimicrobial class.      
1.6.6 Logistical issues 
Participation incentives, funding, data analysis and reporting are just some of the 
logistical issues baring the implementation of effective AMR surveillance programs. 
Surveillance often requires participation from multiple stakeholders including producers, 
microbiology laboratories, regulatory bodies and pharmaceutical companies. 
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Participation may be based on mandatory, randomised or voluntary reporting of AMU or 
AMR data. The associated pros and cons of different schemes as well as legal issues 
regarding prescription only antimicrobials need to be considered1. Funding and 
reporting often go hand in hand, with funding agencies requiring data collection and 
reporting at regular intervals. In fact, isolate collection for surveillance often precedes 
microbial analysis in the face of insufficient funds242. Funding sources vary considerably 
from pharmaceutical companies (MYSTIC), to government agencies (CIPARS) and 
academic institutions (SAVSNET). With respect to funding sources, the potential for 
conflict of interests, particularly when pharmaceutical companies are involved, should 
be identified242. 
 
1.7 Rationale 
The identification of urinary E. coli as an important target for surveillance efforts 
is a relatively recent phenomena in veterinary medicine49. The regularity with which this 
pathogen is isolated in dogs, warrants an investigation into the frequency and 
mechanisms of resistance in this population. The reviewed literature indicates that rates 
of resistance in canine isolates are low compared to synonymous human infections, 
though there is significant geographic variation68,94,151,154,247. For example, resistance is 
more prevalent in Asian and African countries, when compared to Canada and northern 
European countries such as Sweden122,205,212,221–224. In most cases surveillance 
investigations are descriptive and retrospective in nature, relaying the results of 
qualitative susceptibility testing without further investigation of the genetic basis of 
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resistance. The identification of phenotypic AMR, while sufficient for clinical purposes, 
provides an incomplete description of how and why resistance occurs. Molecular 
techniques allow for more extensive investigations into the mechanism of resistance, 
and by extension, provide important epidemiological information about the emergence 
and spread of resistance genes. What’s more, the inclusion criteria, sampling and 
submission procedures, method of susceptibility testing, panel of antimicrobials 
included; and definitions of clinical microbiological parameters such as susceptible, 
resistant and MDR are highly variable across the literature, making generalizing and 
comparing results difficult. These surveillance studies also tend to be passive, relying 
on susceptibility data or diagnostic submissions to regional laboratories. Convenience 
sampling in this way introduces bias in surveillance literature since laboratory 
submissions typically represent scenarios where empirical treatment has failed50.  This 
study aims to develop a pathogen (E. coli) and disease specific (canine UTIs) 
surveillance program within a specified geographic area (Saskatchewan) in order to fill 
the knowledge gap that currently exists regarding the state of AMR in canine urinary E. 
coli in this region. Strict inclusion criteria and robust methods, including standardized 
antimicrobial panels and interoperative criteria, will be applied to gather accurate, local 
resistance data that may be used to establish a baseline for future surveillance, in 
addition to being used by local veterinarians to inform prescribing practices for these 
common infections.  
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1.8 Objectives 
1. To describe the phenotypic resistance profiles of canine urinary E. coli in Western 
Canada during a four-year surveillance period 
2. To characterize the molecular mechanism(s) of antimicrobial resistance among E. 
coli causing canine urinary tract infections in Western Canada during a four-year 
surveillance period 
3. To describe fosfomycin susceptibility and mechanisms of resistance among E. coli 
and S. pseudintermedius isolated from canine UTIs in Saskatchewan 
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2.1 Abstract 
Background: Urinary tract infections are common in veterinary medicine. The urinary 
tract is the most common source of MDR E. coli in canine patients and a treatment 
challenge for clinicians. Surveillance to detect the emergence of AMR in companion 
animal pathogens is lacking in Western Canada.  
Methods: From November 2014 to 2018, 516 non duplicate canine urinary E. coli 
isolates were collected from a diagnostic laboratory. Susceptibility testing was 
performed against a panel of 14 antimicrobials belonging to 7 different drug classes and 
isolates with appropriate phenotypes were screened for production of ESBLs, AmpC -
lactamases and PMQR genes. Epidemiological relationships were assessed by MLST.  
Results: 80.2% (n=516) of isolates were susceptible to all antimicrobials tested. There 
was no significant increase in the proportion of isolates resistant to any of the tested 
antimicrobials during the study period. However, resistance to sulfisoxazole and SXT 
decreased significantly between years three and four (p=0.0073) and three and five 
(p=0.0066) respectively. Resistance to ampicillin was most common (14.9%). Overall, 
twelve isolates harbored CMY-2 type AmpC -lactamases, and seven produced CTX-M 
type ESBLs. A single isolate was found to harbour the aac(6′)- Ib-cr PMQR gene. The 
qnr and qepA determinants were not detected. A single isolate belonging to the 
pandemic lineage ST131 was identified.  
Conclusion: Canine urinary E. coli in Saskatchewan remain susceptible to first line 
therapies, though resistance, particularly to the aminopenicillins, warrants monitoring. 
This is the first description of E. coli ST131 from a companion animal in Canada.  
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2.2 Introduction 
AMR has become a common concern of animal and human health care 
professionals. MDR infections increase the morbidity and mortality of patients and result 
in increased costs to the client and the health care system49,248. In dogs, the urinary 
tract has been implicated as the most common extra intestinal site for MDR E. coli21. 
What’s more, the close contact between humans and their pets has implications for the 
sharing of resistant commensal and pathogenic bacteria between species. While the 
exact role of dogs in this transmission cycle has not been adequately studied, evidence 
of “strain sharing” has been demonstrated with Clostridium difficile and MRSA24–26,28. 
Similarly, multiple studies have shown support for the sharing of E. coli between dogs 
and humans through the simultaneous isolation of MDR strains from cohabitating 
humans and their canine companions in both hospital and home environments22,23.    
Antimicrobials are commonly used in companion animal veterinary practice. One 
study in the United Kingdom estimated that more than one third of consults with canine 
patients resulted in the prescription of antimicrobials42. Uncomplicated or sporadic UTIs 
occur in approximately 14% of dogs that visit a veterinarian in their lifetime, representing 
a frequent reason for the prescription of antimicrobials53. Similar to the case in humans, 
the Gram-negative bacterium E. coli is the most frequent pathogen in UTI cases, 
accounting for upwards of 50% of positive canine urine cultures52,56,68,249. According to 
ISCAID, empirical treatment options include members of the -lactam class; such as 
amoxicillin, or the potentiated sulfonamide, SXT50,54,58. Alternative therapies with a 
broader spectrum of activity, such as fluoroquinolones (enrofloxacin, ciprofloxacin), 
chloramphenicol, doxycycline, fosfomycin and nitrofurantoin should be reserved for 
 - 78 - 
cases where laboratory results indicate a lack of susceptibility to empirical treatments. 
In general, it is considered unnecessary to prescribe these agents in cases of 
uncomplicated cystitis given their relative importance in treating human infections, 
coupled with the increasing frequency of resistance54.  
From a clinical perspective, the most troubling resistance mechanism in canine 
urinary E. coli, include ESBLs, Class C (AmpC) β-lactamases, and PMQR genes103. 
ESBLs are capable of hydrolyzing even those extended-spectrum -lactams that had 
been modified to confer resistance to the first-generation enzymes. The first ESBL 
identified in an animal was isolated from the feces of a healthy laboratory dog in 
Japan250. In general, SHV, TEM and CTX-M type ESBLs are among the most common, 
however since the beginning of the 21st century, CTX-M type enzymes have become 
most prevalent76,110,117. Currently, the most widely distributed CTX-M alleles are CTX-M-
1, -15 and -14, having been isolated from both healthy and diseased companion 
animals103. While CTX-M-1 and CTX-M-15 predominate in Europe, in North America, 
CTX-M-15 is most commonly encountered, particularly among companion animals 
suffering from cystitis29,127,128,135,138,216,251–257. In Asia CTX-M-14 is the dominant enzyme 
type, however, additional ESBLs, including SHV-12 have been identified in companion 
animals in Spain, Germany, China and the U.S.136,253,255,258. AmpC -lactamases confer 
resistance to cephamycins (cefoxitin for example) and “classic” -lactamase inhibitors, 
in addition to ESCs. Most often, AmpC -lactamase producing E.coli acquire these 
enzymes on plasmids119. CMY-2 is the most common type detected in companion 
animals, having been identified in dogs from Japan, Denmark and Canada120–122. 
Fluoroquinolones are a broad-spectrum antimicrobial class that exert their mechanism 
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of action by interfering with DNA replication49. Originally, acquired resistance to 
fluoroquinolones was thought to occur strictly through chromosomal mutation in the 
genes gyrA and parC that encode the drug target45,131. However, the first report of 
PMQR occurred in the late 1990s132. To date, three types of transmissible quinolone 
resistance genes have been reported. The target protecting proteins (qnrA, qnrB, qnrC, 
qnrD and qnrS); the inactivating enzyme aac(6′)- Ib-cr, and the efflux pumps qepA and 
oqxAB45. In companion animals the gene aac(6′)- Ib-cr appears to be the most 
widespread, having been identified in E. coli from both healthy and diseased companion 
animals across Europe, Australia, Asia and the U.S.135–139,142,143. The tendency of the 
aac(6′)- Ib-cr gene to co-locate on plasmids harbouring ESBLs is of particular concern, 
as it provides the framework for the emergence of MDR. In Canada, the efflux pump 
QepA and the Aac(6′)-Ib-cr enzyme have been much more commonly reported than the 
Qnr proteins among urinary E. coli isolated from humans173,175,259. However, we know of 
no studies documenting either of these PMQR determinants in companion animal E. coli 
in Canada. 
The emergence of transmissible AMR among canine urinary E. coli in other 
regions warrants an investigation into the prevalence and mechanisms of resistance in 
this pathogen population in Canada. In fact, various consensus statements in veterinary 
medicine call for more prudent use of antimicrobials by veterinarians and identify urinary 
E. coli as an important target for surveillance studies15,49,50. Unfortunately, national 
surveillance programs in Canada do not address AMR in companion animals, focusing 
instead on food animal pathogens with the potential for foodborne transmission1.  
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Where surveillance literature exists for canine uropathogens, the results indicate 
significant geographic variation in the frequency of resistance. For example, resistance 
is more prevalent in Asian and African countries, compared to Canada and northern 
European countries such as Sweden122,205,212,221–224. Previous work out of 
Saskatchewan detected a particularly low frequency of resistance (~80% pan 
susceptibility) among canine urinary E. coli122. These baseline findings provide a unique 
opportunity to detect the emergence of clinically relevant resistance determinates in this 
region. This study aims to describe the frequency and mechanisms of AMR among E. 
coli causing canine UTIs in Western Canada during a four-year surveillance period. 
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2.3 Materials and Methods 
2.3.1 Microbiological analysis and inclusion criteria 
Canine diagnostic samples submitted to Prairie Diagnostic Services (PDS) in 
Saskatoon, SK were collected from October 2014-2018. Samples were obtained as 
pure cultures plated on 5% Columbia blood agar on a weekly basis. Initial bacterial 
identification was performed at PDS by biochemical testing; including indole, triple sugar 
iron (TSI) agar, urea and citrate (2014-2015); and matrix-based assisted laser 
desorption ionization time-of-flight (MALDI-TOF) mass spectroscopy (2015-2018). In 
cases of suspicious colony morphology or contamination, bacterial identity was 
confirmed based on lactose fermentation on MacConkey agar and the spot indole test. 
Rarely, colony morphology and biochemical tests were insufficient for species 
identification. In these cases, PCR was employed to amplify a universal gene; 16S 
rRNA or cpn60260,261. All isolates were saved for analysis in tryptic soy broth (TSB) plus 
15% glycerol at -80°C. All canine urinary submissions were initially included. 
 In order to be included in the study, isolates had to be confirmed as first-time 
submissions of canine urine with a positive E. coli culture from one of the four western 
Canadian provinces. Data extracted from the PDS database to confirm the identity of 
repeat samples include microbiological information, such as laboratory analytical 
procedure, bacterial species and specimen type; and patient information, including 
animal name, species, breed, age, client surname and case number, where available. 
Geographic information regarding the origin of each submission (client province of 
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origin), was recorded to determine the extent to which our study covered the Western 
Canadian provinces.  
2.3.2 Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing (AST) was performed by the broth 
microdilution technique using the Sensititre system. Briefly, standard 0.5 McFarland 
suspensions were prepared in commercially obtained sterile water (Thermo Fisher 
Scientific) using a fresh overnight culture plated on 5% Columbia agar. A 30 L volume 
of the bacterial suspension was transferred to Sensititre Mueller-Hinton broth. Following 
the application of a dosing head, 50 Ls was auto inoculated onto 96 well plates 
containing two-fold serial dilutions of various antimicrobials. Plates were sealed and 
following overnight incubation at 35C, growth was observed and recorded manually on 
plate schematics obtained on the manufacturer website. We employed the Gram-
negative panel (CMV3AGNF/CMV4AGNF) used by national surveillance studies 
targeting food borne pathogens in Canada and the U.S., which includes 14 
antimicrobials belonging to 7 different classes (Table 2.1). Agents tested include 
ampicillin, amoxicillin-clavulanate, cefoxitin, ceftriaxone, ceftiofur, nalidixic acid, 
ciprofloxacin, gentamicin, tetracycline, chloramphenicol, sulfisoxazole, trimethoprim-
sulfamethoxazole, and azithromycin. This particular panel was updated to include the 
carbapenem meropenem, in place of ceftiofur in 2017. To ensure the AST system 
performed as expected, quality control strains, E. coli ATCC 25922 and S. aureus 
ATCC 29213 were run in parallel with test isolates. Results were interoperated 
according to breakpoints published by CLSI in their M100 (29th ed.) document262. 
These values have taken into account microbiological, pharmacologic and clinical data 
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to synthesize the efficacy of certain drug-bug combinations for the infection under 
investigation and are summarized in Table 2.1. Since some antimicrobial agents tend to 
concentrate in the urine significantly above levels attainable in the blood, where 
available we utilized urine specific breakpoints209. In addition to resistance to these 
drugs, we also report rates of MDR which was defined as resistance to at least one 
antimicrobial in three or more classes263. For the purposes of this study, we consider all 
-lactams as one class.  
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Table 2.1: Antimicrobials, concentrations and breakpoints used for susceptibility testing of E. coli 
(CMV3AGNF/CMV4AGNF)262 
Antimicrobial Concentrations (g/mL) CLSI breakpoint (g/mL) 
CMV3AGNF/CMV4AGNF  
Cefoxitin (FOX) 0.5-32 32 
1Azithromycin (AZI) 0.12-16 32 
Chloramphenicol (CHL) 2-32 32 
Tetracycline (TET) 4-32 16 
Ceftriaxone (AXO) 0.25-64 4 
2Amoxicillin-clavulanate (2:1 ratio) 
(AUG2) 
1/0.5-32/16 
 
32/16 
Ciprofloxacin (CIP) 0.015-4 4 
Gentamicin (GEN) 0.25-16 16 
Nalidixic Acid (NAL) 0.5-32 32 
Ceftiofur (XNL) 0.12-8  8 
3Meropenem (MER) 0.06-4 4 
Sulfisoxazole (FIS) 16-256 512 
Trimethoprim-sulfamethoxazole (SXT) 0.12/2.38-4/76 4/76 
Ampicillin (AMP) 1-32 32 
1Concentrations included for azithromycin AST by broth microdilution were changed to include 32 g/mL in the most 
recent version of the NARMS panel (CMV4AGNF) released in 2017. 
2Amoxicillin-clavulanate contains amoxicillin and clavulanic acid in a 2:1 ratio  
3Ceftiofur was replaced with Meropenem in the most recent version of the NARMS Sensititre panel (CMV4AGNF) 
released in 2017.  
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2.3.3 Detection of resistance genes 
DNA was prepared for PCR using a heat based crude extraction method. From 
fresh overnight culture, four to five colonies were transferred to 200 L of sterile water 
and heated at 95C for ten minutes. The resulting suspension was spun down and the 
supernatant removed and stored at -20C for future use as a DNA template. If 
resistance phenotypes involved third generation cephalosporins, cephamycins or 
fluoroquinolones, isolates were sequentially screened for various resistance genes by 
PCR. General PCR conditions included denaturation at 94C for 6 minutes followed by 
30-35 cycles of denaturation (94C), annealing (various temperatures), and extension 
(72C) for 1 minute each and a final extension step for 10 minutes at 72C. All PCR 
reactions included a no template negative control and a positive control containing DNA 
from an isolate previously determined to be positive for the gene of interest. Primers 
and associated annealing temperatures utilized for all reactions are shown in Table 2.2.  
2.3.3.1 Broad spectrum -lactamases 
All third-generation cephalosporin (ceftriaxone or ceftiofur) resistant isolates were 
initially screened using universal primers for CTX-M type enzymes. Any positive isolates 
were sequentially screened for CTX-M groups 1, 2, 8 and 9. Isolates were additionally 
screened for the SHV and TEM type ESBLs. Cephamycin (cefoxitin) resistant isolates 
were screened for CMY-2 type AmpC -lactamase production. All primers and PCR 
conditions are outlined in Table 2.2.  
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2.3.3.2 Plasmid mediated quinolone resistance determinants 
Nalidixic acid and ciprofloxacin resistant isolates were screened for each of the 
PMQR determinants; qnrA, qnrB, qnrS, aac(6′)-Ib-cr, and qepA using primers 
summarized in Table 2.2. 
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Table 2.2: Primers and PCR conditions 
Name Nucleotide sequence (5’-3’) Amplicon size Annealing 
Temperature 
(C) 
Reference 
16S 
(1476/1478) 
GAGTTTGATCCTGGCTCAG  500 60C 261 
G(TA)ATTACCGCGGC(TG)GCTG 
AAC(6’)-IB-
CR 
CATTGTAGCACGTGTGTA 482 67C 264 
CATTGTAGCATGCG'I"I'GAAG 
ADK CGGTGTGT[AG]CAAGGCCC 583 54C 265 
ACGGCTACCTTGTTACGACTT 
CMY-2 AGAAAGGAGGTGATCCAGCC 1000 68C 266 
GCTTTTCAAGAATGCGCCAGG 
CPN60 
(1594/1595) 
CGCCAGGGTTTTCCCAGTCACGACGACGTCGCCGGTGACGGCACCACCAC 700 57C 260 
AGCGGATAACAATTTCACACAGGACGACGGTCGCCGAAGCCCGGGGCCTT 
CTX-M G1 GTTGTTAATTCGTCTCTTCC 700 61C 267,268 
AGTTTCCCCATTCCGTTTC 
CTX-M G2 ACTCAGAGCATTCGCCGCTCA 1000 58.3C 268 
TTATTGCATCAGAAACCGTG 
CTX-M G8 CGCTTTGCCATGTGCAGCACC 307 64C 269 
GCTCAGTACGATCGAGCC 
CTX-M G9 GACCGTATTGGGAGTTTGAG 600 48C 270,271 
ATCTGATCCTTCAACTCAGC 
CTX-M U ATGTGCAGYACCAGTAARGTKATGGC 593 61C 267 
TGGGTRAARTARGTSACCAGAAYCAGCGG 
FUMC TCACAGGTCGCCAGCGCTTC 806 54C 265 
GTACGCAGCGAAAAAGATTC 
GYRB TCGGCGACACGGATGACGGC 911 61C 265 
ATCAGGCCTTCACGCGCATC 
ICD ATGGAAAGTAAAGTAGTTGTTCCGGCACA 878 54C 265 
GGACGCAGCAGGATCTGTT 
MDH ATGAAAGTCGCAGTCCTCGGCGCTGCTGGCGG 932 54C 265 
TTAACGAACTCCTGCCCCAGAGCGATATCTTTCTT 
PURA CGCGCTGATGAAAGAGATGA 816 54C 265 
CATACGGTAAGCCACGCAGA 
QEPA GCAGGTCCAGCAGCGGGTAG 199 60C 272 
CTTCCTGCCCGAGTATCGTG 
QNRA ATTTCTCACGCCAGGATTTG 516 53.4C 273 
GATCGGCAAAGGTTAGGTCA 
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QNRB GATCGTGAAAGCCAGAAAGG 469 67C 
ACGATGCCTGGTAGTTGTCC 
QNRS ACGACATTCGTCAACTGCAA 417 53C 
TAAATTGGCACCCTGTAGGC 
RECA TCTCGATCAGCTTCTCTTTT 780 61C 265 
CGCATTCGCTTTACCCTGACC 
SHV TTATCTCCCTGTTAGCCACC 797 68C 274 
GATTTGCTGATTTCGCTCGG 
TEM GCGGAACCCCTATTTG 964 58.3C 275 
ACCAATGCTTAATCAGTGAG 
 
 - 89 - 
2.3.3.3 PCR purification and sequencing 
Following PCR, amplicons were further purified using the EZ-10 Spin Column 
PCR Purification Kit, (Bio Basic Canada Inc) or the ExoProStar enzymatic PCR and 
sequence reaction clean up kit (GE Healthcare Life Sciences) according to the 
manufacturer’s instructions. DNA sequencing was performed by Macrogen Inc. 
Obtained sequences were compared to reference genes published in the National 
Center for Biotechnology Information (NCBI) and Comprehensive Antibiotic Resistance 
Databases (CARD) using the Basic Local Alignment Search Tool (BLAST) algorithm. 
 
2.3.4 Molecular epidemiology of ESBL and PMQR producing isolates 
To determine epidemiological relationships between ESBL and PMQR 
producers, we utilize the MLST scheme for E. coli described by the Warwick Institute, 
(http://mlst.warwick.ac.uk/mlst/dbs/Ecoli) as this scheme has the greatest agreement 
with whole genome sequencing (WGS) techniques162,265,276,277. In short, for each isolate, 
seven different housekeeping genes (adk, fumC, gyrB, icd, mdh, purA and recA) were 
amplified by PCR and the purified products were sequenced. Obtained sequences were 
compared to an MLST database (pubMLST), which assigns each allelic profile to a 
sequence type (for example, ST131). Primers and annealing temperatures used for 
these reactions are outlined in Table 2.2. 
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2.3.5 Statistical Analysis 
 Susceptibility data was grouped into susceptible and resistant for each 
antimicrobial across the four years of study. The relationship between the proportion of 
resistant and susceptible isolates to a given antimicrobial and the year of submission 
was assessed using the Fisher’s exact test for low cell frequencies with Bonferroni’s 
correction (p<0.01). The change in the proportion of MDR and pan susceptible isolates 
over time was examined using the Fisher’s exact test with Bonferroni correction 
(p<0.01). The relationship between -lactamase production and the phenotypes MDR 
and fluoroquinolone resistance were also assessed using a Fisher’s exact test (p<0.01).  
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2.4 Results 
2.4.1 Microbiological analysis and inclusion criteria 
 From November 1st, 2014 to October 31st, 2018 710 E. coli isolates were 
obtained from PDS. Non urine (n=28), non-canine (n=24), non-E. coli (n=15) and repeat 
(n=127) isolates were excluded as shown in Table 2.3, leaving a total of 516 non 
duplicate canine urinary E. coli isolates. As shown in Table 2.4, 92.8% (n=479) of 
isolates originated from Saskatchewan, while the remaining 7% was split equally 
between Manitoba (n=18) and Alberta (n=18). A single isolate was submitted from 
British Columbia (n=1).  
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Table 2.3: An overview of excluded isolates (n=194) 
Exclusion Criteria Number of Isolates 
Not urine 28 
Ear/skin swab 10 
Feces 3 
Other 15 
  
Not canine 24 
Equine 1 
Feline 21 
Porcine 2 
  
Not E. coli 15 
Citrobacter spp. 3 
Enterobacter spp. 1 
Enterococcus spp. 6 
Pseudomonas spp. 1 
Staphylococcus pseudintermedius 4 
  
Repeat submissions 127 
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Table 2.4: Geographic distribution of isolates (n=516) 
Province Year 1 Year 2 Year 3 Year 4 Total 
Alberta (n=18) 3 6 2 7 3.5% 
British Columbia 
(n=1) 
0 0 0 1 0.2% 
Manitoba (n=18) 3 1 6 8 3.5% 
Saskatchewan 
(n=479) 
80 139 124 136 92.8% 
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2.4.2 Antimicrobial susceptibility testing 
 There was no statistically significant increase in the frequency of resistance to 
any of the fourteen antimicrobials tested across the study period (Figure 2.1 and 2.2). 
There was a statistically significant decrease in the proportion of isolates resistant to 
sulfisoxazole and SXT observed during the study period (p<0.01) between years three 
and four (p=0.0073) and years three and five (p=0.0066) respectively. Overall, 80.2% of 
isolates were pan susceptible to all antimicrobials tested, while 6.0% exhibited MDR to 
at least three different antimicrobial classes. There was no change in the frequency of 
pan-susceptibility or MDR over the study period. Susceptibility remained above 90% for 
all agents tested except ampicillin (85%). After ampicillin, resistance was most common 
to tetracycline (7.7%), sulfisoxazole (7.3%), nalidixic acid (5.7%), cefoxitin (5.7%) and 
amoxicillin-clavulanate (5.5%). The frequency of resistance for the remaining 
antimicrobials was less than 5%. Meropenem resistance was not detected. The majority 
of isolates resistant to a single antimicrobial class were resistant to -lactams (73%). 
The 31 MDR isolates displayed 26 different resistance profiles as shown in Table 2.5.  
Of the MDR isolates, the majority of phenotypes included resistance to -lactams 
(93.5%) and/or tetracyclines (80.6%). A single isolate was found to be resistant to all 
seven antimicrobial classes included on the panel. 
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Figure 2.1: Number of isolates (n=516) exhibiting resistance across four years of a canine urinary E. coli antimicrobial 
resistance surveillance program. AMP- ampicillin, AUG- amoxicillin-clavulanate, FOX- cefoxitin, AXO- ceftriaxone, XNL-
ceftiofur, MER- meropenem, NAL- nalidixic acid, CIP- ciprofloxacin, GEN- gentamicin, TET- tetracycline, CHL- 
chloramphenicol SOX- sulfisoxazole, SXT- trimethoprim-sulfamethoxazole, and AZI- azithromycin 
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 Percentage of all isolates with MIC (g/mL) 
Antimicrobial 0.015 0.03 0.06 0.12 0.25 0.5 1.0 2.0 4.0 8.0 16.0 32.0 64.0 128 256 512 Resistant 
(%) 
Ampicillin       1.9 22.7 50.8 8.7 0.97 0 14.9    14.9 
Amox/Clav       0.78 5.2 57.9 27.9 2.7 2.1 3.3    5.4 
Cefoxitin      0 1.2 9.3 48.4 30.6 4.8 2.3 3.3    5.6 
Ceftriaxone     94.2 0.97 0.39 0.39 0.19 0.19 1.4 0.58 0 1.7   4.1 
Ceftiofur1    3.0 12.3 65.9 12.3 1.3 0.66 1.3 3.3      4.6 
Meropenem1   99.1 0.94 0 0 0 0 0 0       0 
Nalidixic Acid      0.39 4.7 53.1 33.5 2.5 0.19 0 5.6    5.6 
Ciprofloxacin 53.3 36.8 2.7 2.1 1.6 1.2 0.39 0 0 1.9       1.9 
Gentamicin     3.1 41.3 46.9 5.6 1.6 0.19 0.19 1.2     1.4 
Tetracycline         89.9 2.7 0.78 0.39 6.2    7.4 
Chloramphenicol        0.58 4.3 59.3 33.7 0.97 1.2    2.1 
Sulfisoxazole           51 30.2 9.1 1.9 0.58 7.2 7.2 
SXT    95.9 1.4 0.58 0.39 0 0 1.7       1.7 
n=516  
1N=302 for ceftiofur as ceftiofur was replaced with meropenem in the most recent version of the NARMS panel (CMV4AGNF) released in 2017 
Figure 2.2: An MIC distribution of canine urinary E. coli isolates (n=516) collected from November 2014-October 2018. 
Breakpoints (indicated in red) are based off of published CLSI standards  
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Table 2.5: Resistance profiles of multidrug resistant isolates (n=31)  
Phenotype Number of 
Isolates 
AMP + TET + SOX 5 
FOX + NAL + CHL 1 
TET + SOX + AZI 1 
AMP + TET + SOX + SXT 1 
AMP + NAL + CIP + SOX 1 
AMP + NAL + SOX + SXT + AZI 1 
AMP + GEN + SOX + SXT + AZI 1 
AMP + AUG + FOX + TET + SOX 1 
AMP + AXO + NAL + CIP + SOX 1 
AMP + AXO + TET + CHL + SOX 1 
AMP + FOX + TET + CHL + SOX 1 
NAL + CIP + TET + CHL + SOX 1 
AMP + AUG + FOX + AXO + TET + SOX 1 
AMP + TET + CHL + SOX + SXT + AZI 1 
AMP + AUG + FOX + AXO + NAL + TET 1 
AMP + NAL + CIP + TET + SOX + AZI 1 
AMP + NAL + TET + GEN + SOX + SXT + AZI 1 
AMP + AUG + FOX + XNL + NAL + GEN + SOX 1 
AMP + AXO + XNL + NAL + TET + SOX + SXT 1 
AMP + AXO + XNL + NAL + CIP + TET + CHL + AZI  1 
AMP + AUG + FOX + AXO + XNL + TET + CHL + SOX 1 
AMP + AUG + FOX + AXO + XNL + GEN + TET + SOX 1 
AMP + AXO + NAL + CIP + TET + SOX + SXT + AZI 1 
AMP + AUG + FOX + AXO + XNL + NAL + CIP + TET + SOX 2 
AMP + AUG + FOX + AXO + XNL + GEN + TET + CHL + SOX 1 
AMP + AXO + XNL + NAL + GEN + TET + CHL + SOX + SXT + AZI 1 
  
 - 98 - 
2.4.3 Detection of resistance genes 
 Of 516 isolates, 4.3% (n=22) exhibited resistance to the third generation 
cephalosporins ceftriaxone (MIC4) and/or ceftiofur (MIC8). Of the ESBLs detected, 
CTX-M-27 was the most prevalent (n=3) followed by CTX-M-15 (n=2) and CTX-M-14 
(n=2). One of the CTX-M 27 producers displayed resistance to all seven antimicrobial 
classes tested (Table 2.6). There was no significant change in the frequency of CTX-M 
producing isolates observed over the study period. SHV and TEM type ESBLs were not 
detected. Of 22 third generation cephalosporin resistant isolates, 68% were also 
cefoxitin resistant (MIC32), of which 12 produced CMY-2 type AmpC  -lactamases 
(Table 2.6). There was no significant change in the frequency of CMY-2 producing 
isolates across the study period. The overall occurrence of AmpC -lactamases and 
ESBLs in our isolates collection was 2.3% and 1.3% respectively. Broad spectrum -
lactamase production (CTX-M or CMY-2 type enzymes) was significantly associated 
with MDR (p=0.0001) and fluoroquinolone resistance (p=0.0002). The PMQR 
determinant aac(6′)- Ib-cr was identified in a single isolate that was also MDR to four 
antimicrobial classes. A broad spectrum -lactamase (SHV, TEM, CTX-M or CMY-2) 
was not detected in this isolate. 
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Table 2.6: Phenotypic and genomic characteristics of -lactamase producing E. coli isolated from canine urinary samples 
Isolate  Year Phenotype Genotype 
ECPDS140 1 AMP + AUG + FOX + AXO + XNL + GEN + TET + CHL + SOX blaCMY-2 
ECPDS155 1 AMP + AUG + FOX + AXO + XNL + TET + CHL + SOX blaCMY-2 
ECPDS202 1 AMP + AXO + XNL + NAL + TET + SOX + SXT  blaCTX-M-15 
1ECPDS218 2 AMP + AUG + FOX + AXO + XNL + NAL + CIP + TET + SOX aac(6′)- Ib-cr 
ECPDS236 2 AMP + AXO + XNL  blaCTX-M-15 
ECPDS264 2 AMP + AUG + FOX + AXO + TET + SOX blaCMY-2 
ECPDS272 2 AMP + AUG + FOX + AXO + XNL + GEN + TET + SOX blaCMY-2 
ECPDS289 2 AMP + AUG + FOX + AXO + XNL + NAL + CIP + TET + SOX blaCMY-2 
ECPDS306 2 AMP + AUG + FOX + XNL + NAL + GEN + SOX blaCMY-2 
ECPDS318 2 AMP + AXO + XNL + NAL + GEN + TET + CHL + SOX + SXT + AZI  blaCTX-M-27 
ECPDS426 2 AMP + AUG + FOX + AXO + XNL blaCMY-2 
ECPDS462 3 AMP + AUG + FOX + AXO + XNL blaCMY-2 
1ECPDS464 3 AMP + AUG + FOX + AXO + XNL + AZI - 
1ECPDS465 3 AMP + AUG + FOX + AXO + XNL - 
ECPDS494 3 AMP + AXO + XNL + NAL + CIP + TET + CHL + AZI  blaCTX-M-14 
ECPDS537 3 AMP + AUG + FOX + AXO + NAL + TET blaCMY-2 
ECPDS538 3 AMP + AUG + FOX + AXO + AZI blaCMY-2 
ECPDS552 3 AMP + AXO + NAL + CIP + TET + SOX + SXT + AZI  blaCTX-M-27 
ECPDS580 3 AMP + AUG + FOX + AXO + NAL blaCMY-2 
ECPDS682 4 AMP + AUG + FOX + AXO blaCMY-2 
ECPDS698 4 AMP + AXO + NAL + CIP + SOX blaCTX-M-27 
ECPDS749 4 AMP + AXO + TET + CHL + SOX blaCTX-M-14 
1These isolates did not  possess one of the -lactamases that was screened for (SHV, TEM, CTX-M or CMY-2)
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2.4.4 Molecular epidemiology 
 MLST was performed on seven ESBL producers, as well as the single isolate 
harbouring the aac(6′)- Ib-cr gene (Table 2.7). Two isolates belonged to ST38; one 
possessed an aac(6′)- Ib-cr gene, while the other produced the ESBL CTX-M-27. The 
remaining isolates belonged to distinct sequence types including ST10, ST12, ST117, 
ST131, ST648 and ST1193. The isolates producing CTX-M-14 belonged to ST117 and 
ST648. The isolates harbouring CTX-M-15 belonged to ST10 and ST12. The two 
remaining CTX-M-27 producers belonged to ST131 and ST1193. 
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Table 2.7: Phenotypic and genomic characteristics of CTX-M and PMQR producing E. coli isolated from canine urinary 
samples 
Isolate Phenotype Genotype ST 
ECPDS202 AMP + AXO + XNL + NAL + TET + SOX + SXT blaCTX-M-15 ST10 
ECPDS218 AMP + AUG + FOX + AXO + XNL + NAL + CIP + TET + SOX aac(6′)- Ib-cr ST38 
ECPDS236 AMP + AXO + XNL blaCTX-M-15 ST12 
ECPDS318 AMP + AXO + XNL + NAL + GEN + TET + CHL + SOX + SXT + AZI blaCTX-M-27 ST131 
ECPDS494 AMP + AXO + XNL + NAL + CIP + TET + CHL + AZI blaCTX-M-14 ST648 
ECPDS552 AMP + AXO + NAL + CIP + TET + SOX + SXT + AZI blaCTX-M-27 ST1193 
ECPDS698 AMP + AXO + NAL + CIP + SOX blaCTX-M-27 ST38 
ECPDS749 AMP + AXO + TET + CHL + SOX blaCTX-M-14 ST117 
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2.5 Discussion and Conclusion 
The most recent treatment guidelines from ISCAID recommend amoxicillin or 
SXT and, if amoxicillin alone is not available, amoxicillin-clavulanate for the empirical 
treatment of uncomplicated cystitis in canine patients54. On the other hand, 
nitrofurantoin, fluoroquinolones, doxycycline, chloramphenicol, and fosfomycin are 
considered alternative treatments for MDR pathogens54. Our findings suggest that 
canine urinary E. coli in Saskatchewan remained remarkably susceptible to commonly 
prescribed antimicrobials. In fact, the proportion of isolates resistant to sulfisoxazole and 
SXT, decreased significantly during the study period. While this decrease in resistance 
to sulfisoxazole is not particularly clinically relevant since sulfonamides are not used in 
isolation in companion animals, SXT is considered a good first line option for treating 
UTIs and has historically been commonly prescribed. 
Resistance to ampicillin was most common (~15%), while fluoroquinolone 
susceptibility remained remarkably high (~98%) in this isolate population (n=516). This 
is in contrast to AMR trends observed in urinary E. coli of human origin68,150–152,154. In 
fact, a lack of efficacy coupled with the alarming rates of resistance reported recently, 
have caused the IDSA to remove both amoxicillin and fluoroquinolones from their 
treatment guidelines for uncomplicated cystitis. Specifically, fluoroquinolones are to be 
reserved for important uses other than cystitis64. In general, clinical guidelines 
recommend that local resistance rates exceeding 10% indicate an emerging resistance 
problem and the need to adjust empirical treatment choices for antimicrobial therapy50. 
While the ampicillin resistance rate reported here (~15%) is concerning, ampicillin is not 
the aminopenicillin of choice for treating canine patients with cystitis. Amoxicillin, the 
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oral formulation used in practice, achieves extraordinarily high concentrations in the 
urine and bladder in vivo, which exceed the breakpoint used to interoperate in vitro 
susceptibility results54. This fact highlights the limitations of using indicator drugs and 
the importance of integrating the results of laboratory tests with clinical judgment and 
knowledge of pharmacology, when making decisions about prudent AMU. 
Two previous studies have investigated phenotypic and genomic resistance 
among canine urinary E. coli in this region. A previous investigation, corresponding to 
the first year of passive surveillance completed by our group, found similar rates of 
susceptibility to those identified here, including a significant proportion of isolates 
exhibiting pan susceptibility to all antimicrobials tested (79.6%), reduced susceptibility to 
ampicillin (8.8%), and extremely low levels of quinolone resistance with just 7% of 
isolates exhibiting resistance to nalidixic acid and <2% displaying ciprofloxacin 
resistance122. A single CMY-2 type AmpC -lactamase producers was identified and no 
ESBLs were detected122. Similar to our findings, a 2008 study reported no change in the 
number of antimicrobials to which non recurrent urinary E. coli were resistant from 
2002-2007205. They also reported an increase in susceptibility (as measured by an 
increase in antimicrobial impact factor) to SXT205. However, this study differed from ours 
in many ways. While our group performed passive surveillance through quantitative 
susceptibility testing of isolates collected in real time, this investigation presented a 
retrospective analysis of laboratory susceptibility data and did not perform any 
susceptibility or molecular testing. The authors also assessed and reported changes in 
susceptibility and clinical efficacy based on antimicrobial impact factor, which takes into 
account the prevalence of a pathogen. This is in contrast to the current study, where we 
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report MICs and corresponding rates of susceptibility and resistance on an agent by 
agent basis over time. These factors make it somewhat difficult to draw comparisons 
between studies. However, from a surveillance perspective, the strict inclusion criteria 
and molecular techniques employed here provide a more complete picture of the state 
of resistance among urinary E. coli in this region.  
From an epidemiological perspective our results have allowed us to describe the 
emergence of important AMR mechanisms in this region. In contrast to our previous 
findings, here we report the emergence of ESBLs of the CTX-M type, the PMQR 
determinant aac(6′)-Ib-cr and the  pandemic clone E. coli ST131 in companion animal 
urinary pathogens in Saskatchewan. CTX-M type ESBLs are a globally disseminated 
and highly transmissible form of ESC resistance that is most commonly reported among 
E. coli causing community acquired cystitis in humans76. CTX-M type enzymes have 
been identified in canine urinary E. coli in Australia, Europe, Asia and the 
U.S.29,127,135,136,138,216,226,251,253–256,278. In Canada, CTX-M-15 is the most common ESBL 
identified in the human literature152,156,166 Though the frequency of CTX-M producers 
was low in our canine isolates, the alleles CTX-M-15 and -14 were detected in addition 
to CTX-M-27, which is closely related to CTX-M-14. Co-resistance to fluoroquinolones is 
a well-documented phenomenon among ESBL producing urinary E. coli in human 
medicine that was also found in the present study166. However, of the three 
fluoroquinolone resistant ESBL producers reported here none possessed the allele 
CTX-M-15, which is detected most frequently among isolates displaying fluoroquinolone 
resistance in the human literature166.  
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The PMQR determinants qnr, aac(6′)-Ib-cr and qepA have been particularly 
thoroughly investigated in the human literature. The aac(6′)-Ib-cr gene is the most 
widely disseminated PMQR determinant, having been identified in E. coli from both 
healthy and diseased companion animals across Europe, Australia, Asia and the 
U.S.135–139. Here, we provide the first description of Aac(6′)-Ib-cr producing E. coli from 
companion animals in Canada. E. coli harboring aac(6′)- Ib-cr have been detected often 
in community acquired UTIs from humans and frequently co-produce CTX-M type 
ESBLs166,173. The tendency of the aac(6′)- Ib-cr gene to co-locate on plasmids 
harbouring ESBLs is of particular concern, as it provides the basis for the emergence of 
MDR strains. In fact, here we identify E. coli ST131 for the first time in a clinical isolates 
of companion animal origin in Canada. This globally prevalent clone is one such 
example where fluoroquinolone resistance and ESBL production came together to 
produce a highly pathogenic and MDR urinary E. coli strain186.  
Epidemiologically, AMR spreads in one of two ways; by the clonal dissemination 
of a single resistant strain or by non-clonal mechanisms including the horizontal transfer 
of resistance determinants in an otherwise heterogenous population. While the high 
prevalence of ST131 among community acquired UTIs in the human literature is one 
such example of clonal spread, the results of the current study more closely reflect the 
second mechanism185,186. Not only did the seven ESBL producing isolates identified 
exhibit seven distinct phenotypic resistance profiles, but the results of MLST indicate 
that these isolates also belonged to seven distinct lineages (Table 2.7). Taken together, 
these findings suggest that the population of urinary E. coli in our region is genetically 
heterogenous and that resistance has most likely emerged by the horizontal 
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dissemination of resistance genes on mobile genetic elements. In fact, among 
companion animal pathogens, there is a lack of evidence for a concrete linkage 
between a specific gene and a certain sequence type. For example, in E. coli isolates, 
ESBL production has been identified in a variety of sequence types255,257,279,280. 
However, there is some evidence that ESBL production is more frequently identified 
among E. coli belonging to certain lineages (ST10, ST23, ST38, ST88, ST131, ST167, 
ST410 and ST648) including those identified in this investigation (ST10, ST38, ST131 
and ST648)257,279,281,282.  
The current study applied a rigorous inclusion criteria and gold standard 
microbiological methods, including quantitative susceptibility testing and molecular 
epidemiological techniques (MLST) to describe AMR among canine urinary E. coli in 
Saskatchewan. Our susceptibility testing methods were chosen over other agar-based 
techniques in an attempt to balance cost with the informative nature of the data 
obtained and the time required to perform the assay. Disk diffusion is a technique 
commonly employed in veterinary diagnostic labs. However, compared to the numeric 
MIC value obtained by microdilution methods, its results are limited to a qualitative 
description of bacterial phenotype as susceptible, intermediate or resistant91. This fact 
limits the information which may be generated from the results. Numerical MICs allows 
us to detect reduced susceptibility where bacteria are able to grow at increasing 
antimicrobial concentrations, while still remaining clinically susceptible. This 
phenomenon would be missed by disk diffusion methods because interpretation is 
strictly categorical. Such information is important as it provides clues regarding the 
molecular development of resistance. For example, while spontaneous mutations may 
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cause an increase in MIC by one or two dilutions, the acquisition of resistance genes by 
horizontal gene transfer tends to cause a substantial increase in MIC from susceptible 
into resistant ranges.  
 Despite these strengths, this investigation presents some limitations worthy of 
discussion. First, this was a passive surveillance study based on convenience sampling 
of laboratory isolates and as such our sample size is limited. Though every attempt was 
made to exclude repeat submissions, isolates submitted for culture and susceptibility in 
veterinary medicine are generally representative of treatment failures since most UTIs 
are initially treated empirically. It is also possible that isolates collected early on in the 
study period represent repeat submissions from before surveillance began. What’s 
more, the vast majority of our isolates (~93%) originated from Saskatchewan, which 
significantly limits the generalizability of our results to the Western Canadian region we 
strove to capture. Second, there was a lack of clinical information regarding previous 
antimicrobial treatment, co morbidities, clinical outcome and AMU data that may provide 
a more complete explanation of risk factors for the emergence of resistance in canine E. 
coli. Finally, the low frequency of resistance detected here, coupled with the relatively 
short duration of this study, limits the statistical power of analyzing and drawing 
conclusions about changes in resistance over time. However, as the aim of this study 
was to identify and report trends and mechanisms of AMR in a surveillance fashion, 
many of these specific clinical questions are outside the scope of this investigation. 
Overall, there are very few limitations associated with susceptibility testing as even 
results that indicate a high frequency of susceptibility are very informative. However, the 
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lack of urine specific breakpoints for many drugs does limit our ability to say with 
complete confidence that an isolate is clinically resistant9. 
As the first of its kind in this region, the robust methodology applied here, 
provides a strong example of disease specific AMR surveillance and its application to 
companion animal pathogens. These findings offer invaluable information about region 
specific AMR trends for companion animal veterinarians in informing empirical treatment 
of UTI, while also establishing a baseline for future surveillance activities. What’s more, 
the isolate collection acquired in this study may be drawn upon in future investigations 
to answer more specific clinical questions. 
In conclusion, canine urinary E. coli remain largely susceptible to first line 
therapies, though resistance, particularly to the aminopenicillins, warrants continued 
monitoring. This is the first molecular description of ESBL and PMQR production in 
canine urinary E. coli in Canada, as well as the first report of E. coli ST131 from a 
companion animal.  
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2.6 Transition statement 
 In order to obtain an isolate collection that is reflective of canine UTIs caused by 
E. coli, 67 isolates were initially excluded. To further establish a population that is 
reflective of uncomplicated UTIs, 127 additional isolates were removed from analysis. 
These isolates represented cases where repeat urine samples were culture positive for 
E. coli from the same patient during the study period. In total, 643 canine urinary E. coli 
were collected across the four-year study. Therefore, repeat isolates represented a 
substantial proportion (~20%) of our collection. Though clinical data was both beyond 
the scope of this investigation and not readily available, these repeat submissions are 
suggestive of treatment failure despite clinicians having access to susceptibility results. 
While underlying pathology alone may be responsible for this apparent lack of 
antimicrobial efficacy, increasing frequency of MDR infections or a lack of availability of 
effective agents might also be contributing. In any case, there is a need to investigate 
alternative antimicrobials for the treatment of UTIs. One such agent that has been 
reached for in human medicine is fosfomycin. In fact, the most recent treatment 
guidelines from the IDSA (human) and ISCAID (veterinary) include fosfomycin. While in 
humans it is considered an appropriate empirical treatment for sporadic cystitis, in 
veterinary medicine, fosfomycin is reserved for infections where MDR has been 
demonstrated. Yet, very little is known about the in vitro susceptibility of canine urinary 
E. coli to fosfomycin. The following chapter aims to fill this knowledge gap by 
investigating fosfomycin resistance among E. coli and S. pseudintermedius isolated 
from canine UTIs in Saskatchewan.  
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3.1 Abstract 
Background: E. coli and S. pseudintermedius are the two most common causes of 
canine UTIs. The emergence of resistance to first line antimicrobials, including ESBL 
and AmpC -lactamase producing E. coli and MRSP, pose a treatment challenge for 
veterinarians. Fosfomycin is an inhibitor of cell wall synthesis used in the treatment of 
uncomplicated UTIs in people, and rarely, companion animals. The objective of this 
study was to determine the frequency of fosfomycin resistance among canine urinary E. 
coli and S. pseudintermedius obtained from a local diagnostic laboratory.  
Methodology: A total of 387 isolates, including E. coli (n=274) and S. pseudintermedius 
(n=113) from canine urine specimens were included. Laboratory requisitions were 
reviewed to ensure that only one isolate per patient was included. Fosfomycin MICs 
were determined by agar dilution. Plates containing serial dilutions of fosfomycin from 
0.25-64 𝜇g/mL + 25 𝜇g/mL glucose-6-phosphate (G6P) were included, and MICs were 
interpreted utilizing EUCAST breakpoints for E. coli and Staphylococcus spp.  
Results: The vast majority of isolates were susceptible to fosfomycin. Seven E. coli 
(2.6%) and four S. pseudintermedius (3.5%) were resistant. Of the fosfomycin resistant 
E. coli, one also possessed an CMY-2 type AmpC -lactamase. Of the fosfomycin 
resistant S. pseudintermedius, three were methicillin resistant.  
Conclusion: The increasing rate of AMR among the canine urinary pathogens E. coli 
and S. pseudintermedius mirrors the emergence of resistance seen in human infections. 
Our results indicate that fosfomycin resistance is not yet common in canine urinary 
pathogens, although continued surveillance is required to identify changes in resistance.  
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3.2 Introduction 
 The emergence of resistance to clinically important antimicrobials has 
veterinarians and physicians alike reaching for alternative treatments for common 
infections. Particularly troublesome, is the emergence of ESBL producing E. coli, as a 
cause of uncomplicated or sporadic cystitis, in both human and canine patients69,73.  
The phosphonic acid derivative fosfomycin, was originally discovered in 1969 
and has long been approved in European and Asian countries for the treatment of 
UTIs283. It’s unique structure, pharmacokinetics and mechanism of action make 
fosfomycin especially desirable for the treatment of cystitis. Fosfomycin inhibits cell wall 
synthesis in both Gram-negative and Gram-positive organisms by acting as a 
phosphoenolpyruvate (PEP) analogue and interfering with the enzyme UDP- GlcNAc 
enolpyruvyl transferase (MurA) involved in the committed step of peptidoglycan 
synthesis284. What’s more, fosfomycin is bactericidal, excreted predominantly 
unchanged in the urine over a prolonged period and has very low toxicity283. Fosfomycin 
also boasts a broad spectrum of activity that includes infections caused by the Gram-
positive cocci S. aureus (including methicillin resistant strains), E. faecalis (including 
vancomycin resistant strains), S. epidermidis, E. faecium and S. pneumoniae283. 
Fosfomycin tromethamine has only recently been approved in the United States for the 
treatment of uncomplicated cystitis caused by susceptible E. coli and E. faecalis strains. 
It is administered as a single oral dose containing 3 g of fosfomycin tromethamine75. 
This single dosing regime is attractive from the context of patient convenience and 
compliance, while simultaneously minimizing selective pressure for resistance as 
uropathogens are exposed for a relatively short period77,283. Despite its relative novelty 
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in North America, the most recent recommendations from the IDSA place fosfomycin in 
the category of appropriate empirical treatment options for uncomplicated UTIs, 
alongside nitrofurantoin, SXT and pivmecillinam64.  
Following its resurgence to clinical use in human medicine, mechanisms of 
resistance to fosfomycin have been extensively studied recently. Resistance to 
fosfomycin occurs by three main mechanism and may be either chromosomally or 
plasmid encoded in both Gram-positive and Gram-negative organisms283. Target 
modification, including chromosomal mutations in the active site of the MurA enzyme 
are encountered infrequently, though they have been described in resistant E. coli285,286. 
Acquired fosfomycin resistance due to impaired uptake occurs more frequently in 
clinical isolates. Specifically, mutations in the glycerol-3-phosphate (glpT) and hexose-
phosphate (uhpT, uhpA) transporters or their regulatory genes is common103,283. 
Multiple fosfomycin-modifying enzymes; including a glutathione transferase (fosA), a 
thiol transferase (fosB) a hydrolase (fosX) and two kinases (fomA and fomB) have also 
been described in E. coli76,103. Many of the genes encoding these enzymes have been 
identified on plasmids in Gram-negative (namely fosA) and Gram-positive (fosB) 
organisms alongside additional resistance determinants144,145. In fact, the plasmid 
mediated resistance gene fosA3 has been identified in animals with no previous 
fosfomycin exposure, suggesting that resistance can be co-selected for in the face of 
exposure to other agents103.  The first report of fosA3 in a companion animal occurred in 
dogs and cats in China in 2012 and 2013. Since then, fosA3 has emerged as the most 
common fosfomycin resistance mechanism among companion animals and appears to 
be particularly widespread in canine populations in China146–148.   
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Though there are comparably few studies in North America, fosfomycin remains 
remarkable efficacious against urinary E. coli from both humans and companion 
animals, with susceptibility rates in excess of 95% among both ESBL and non ESBL 
producing populations73,94,96,287. Recently, the emergence of fosA3 has been 
documented in an E. coli isolate collected from a human patient with recurrent UTIs in 
Pennsylvania288. Compared to Gram-negative infections, even less is known about 
mechanisms of fosfomycin in Gram-positive organisms in North America. However, a 
2014 study identified a particularly high frequency of canine MRSP harbouring fosB, 
even among phenotypically susceptible strains98. While all of these isolates originated 
from skin infections, as the second most common cause of canine cystitis, fosfomycin 
susceptibility in urinary S. pseudintermedius is worthy of investigation289.  Given the lack 
of information regarding susceptibility of canine uropathogens to fosfomycin in Canada, 
this study aimed to describe fosfomycin susceptibility and mechanisms of resistance 
among E. coli and S. pseudintermedius isolated from canine UTIs in Saskatchewan.   
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3.3 Materials and Methods 
3.3.1 Microbiological analysis and inclusion criteria 
Canine diagnostic samples submitted to PDS in Saskatoon, Saskatchewan were 
collected from October 2013 to July 2016. Samples were obtained as pure cultures 
plated on 5% Columbia blood agar on a weekly basis. Initial bacterial identification was 
performed at PDS by biochemical testing (2013-2015) and MALDI-TOF mass 
spectroscopy (2015-2016). Biochemical tests included; for E. coli, metabolism of indole, 
TSI agar, urea and citrate; and for S. pseudintermedius the methyl red, coagulase, 
DNase, and hyaluronidase tests. All canine urinary E. coli and S. pseudintermedius 
submissions were initially included. In cases of suspicious colony morphology or 
contamination, bacterial identity as E. coli was confirmed based on lactose fermentation 
on MacConkey agar and the spot indole test290,291. Identification of S. pseudintermedius 
was confirmed based on colony morphology, Gram staining, coagulase, catalase and 
oxidase tests. Rarely, colony morphology and biochemical tests were insufficient for 
species identification. In these cases, PCR was employed to amplify a universal gene; 
16S rRNA or cpn60260,261. All isolates were saved for analysis in TSB + 15% glycerol at 
-80°C for analysis.  
 Inclusion criteria was applied such that only one submission per dog was 
included over the study period. Data extracted from the PDS database to confirm the 
identity of repeat samples include microbiological information, such as laboratory 
analytical procedure, bacterial species and specimen type; and patient information, 
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including animal name, species, breed, age, client surname and case number, where 
available.  
3.3.2 Antimicrobial susceptibility testing 
3.3.2.1 Preparation of media 
Fosfomycin MICs were determined by the agar dilution method. Stock solutions 
of 500 𝜇g/mL G6P solutions were made as 12 mL aliquots and saved at -80°C prior to 
use. All G6P solutions were passed through a sterile filter to prevent contamination. 
From a stock solution containing 2,560 g/mL in water, nine 1:2 serial dilutions of 
fosfomycin were created. On the day of testing, an equivalent volume of 500 𝜇g/mL 
G6P was added to each fosfomycin dilution.  
For AST ten plates containing nine, two-fold dilutions of fosfomycin (0.25-64 
𝜇g/mL) were used, plus a negative control containing only G6P. To each 18 mL tube of 
Mueller Hinton agar, 2 mL of the appropriate fosfomycin/G6P combination were added 
(1 mL sterile water + 1 mL G6P for control plate) such that each plate contained 1mL 
fosfomycin + 1 mL 25 g/mL G6P. Plates were poured, left to cool and stored at 4°C 
overnight. All media was created less than 24 hours prior to susceptibility testing. 
3.3.2.2 Susceptibility testing (agar dilution) 
Susceptibility testing was performed according to the agar dilution method. 
Briefly, standard 0.5 McFarland suspensions were created in sterile water for each 
organism (E. coli and S. pseudintermedius) using a fresh overnight culture plated on 5% 
Columbia agar. Each suspension was diluted 1:10 and 2 Ls of the subsequent solution 
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was inoculated onto each of the ten agar plates containing fosfomycin + 25 g/mL G6P 
using a multichannel pipette. Each plate was inoculated with three quality control strains 
(E. faecalis ATCC 29212, E. coli ATCC 25922 and S. aureus ATCC 29213), one 
negative control and twenty-eight test isolates based on a pre-determined schematic. 
Following incubation at 35C for 18-24 hours growth was observed, and the MIC 
determined manually. Fosfomycin susceptibility was interoperated according to the 
breakpoints published by EUCAST. In the case of E. coli, these values were for urinary 
isolates specifically. However, as there are currently no official fosfomycin breakpoints 
published specifically for S. pseudintermedius, the criteria for Staphylococcus spp. was 
used (Table 3.1 and Table 3.2).    
3.3.2.3 Susceptibility testing (broth microdilution) 
Susceptibility testing to a panel of additional antimicrobials was performed using 
the broth microdilution technique as follows. Standard 0.5 McFarland suspensions were 
prepared for each organism, in commercially obtained sterile water (Thermo Fisher 
Scientific) using a fresh overnight culture plated on 5% Columbia agar. A 30 L volume 
of the bacterial suspension was transferred to Sensititre Mueller-Hinton broth. Following 
the application of a dosing head, 50 Ls was auto inoculated onto 96 well plates 
containing two-fold serial dilutions of various antimicrobials (Table 3.1 and 3.2). Plates 
were sealed and following overnight incubation at 35 C, growth was observed and 
recorded manually on plate schematics obtained on the manufacturer website. We 
employed the Gram-negative (CMV3AGNF) and Gram-positive (GPALL1F) panels for 
E. coli and S. pseudintermedius respectively. The specific antimicrobials and 
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concentrations included are summarized in Table 3.1 and 3.2. To ensure the AST 
system performed as expected, quality control strains, E. coli ATCC 25922, S. aureus 
ATCC 29213 and E. faecalis ATCC 29212 were run in parallel with test isolates. Results 
were interoperated according to standardized criteria (breakpoints) published by CLSI in 
their M100 document262. These values have taken into account microbiological, 
pharmacologic and clinical data to synthesize the efficacy of certain drug-bug 
combinations for the infection under investigation and are summarized in Table 3.1 and 
3.2. Since some antimicrobial agents tend to concentrate in the urine high above levels 
attainable in the blood, where available urine specific breakpoints were used209. In 
addition to resistance to these drugs, we also report rates of MDR which was defined as 
resistance to at least one antimicrobial in three or more classes263. For the purposes of 
this study, we consider all -lactams as one class.
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Table 3.1: Antimicrobials, concentrations and breakpoints used for susceptibility testing 
of E. coli (CMV3AGNF) 
Antimicrobial Concentrations (g/mL) CLSI breakpoint (g/mL) 
Cefoxitin (FOX) 0.5-32 32 
Azithromycin (AZI) 0.12-16  32 
Chloramphenicol (CHL) 2-32 32 
Tetracycline (TET) 4-32 16 
Ceftriaxone (AXO) 0.25-64 4 
1Amoxicillin-clavulanate 
(AUG) 
1/0.5-32/16 32/16 
Ciprofloxacin (CIP) 0.015-4 4 
Gentamicin (GEN) 0.25-16 16 
Nalidixic Acid (NAL) 0.5-32 32 
Ceftiofur (XNL) 0.12-8 8 
Sulfisoxazole (FIS) 16-256 512 
Trimethoprim-
sulfamethoxazole (SXT) 
0.12/2.38-4/76 4/76 
Ampicillin (AMP) 1-32 32 
2,3Fosfomycin (FOS) 0.25-64 64 (EUCAST) 
1Amoxicillin-clavulanate contains amoxicillin and clavulanic acid in a 2:1 ratio 
2Fosfomycin susceptibility testing was performed using the agar dilution technique 
3Fosfomycin breakpoints were obtained from the European Committee on Antimicrobial Susceptibility 
testing. 
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Table 3.2: Antimicrobials, concentrations and breakpoints used for susceptibility testing 
of S. pseudintermedius (GPALL1F) 
Antimicrobial Concentrations (g/mL) CLSI breakpoint (g/mL) 
Chloramphenicol (CHL) 2-16 32 
Daptomycin (DAP) 0.5-4  
Gentamicin (GEN) 2-16 16 
Linezolid (LZD) 1-8 8 
Rifampin (RIF) 0.5-4 4 
Trimethoprim-
sulfamethoxazole (SXT) 
0.5/9.5-4/76 4 
Quinupristin/dalfopristin 
(SYN) 
0.5-4 4 
Tetracycline (TET) 2-16 16 
Tigecycline (TGC) 0.03-0.5  
Oxacillin + 2% NaCl (OXA) 0.25-4 4 
Ampicillin (AMP) 0.12-8  
Penicillin (PEN) 0.06-8 0.25 
Vancomycin (VAN) 0.25-32 16 
Levofloxacin (LEVO)   0.25-4 4 
Ciprofloxacin (CIP) 1-2 4 
Moxifloxacin (MXF) 0.25-4 2 
Erythromycin (ERY)  0.25-4  8 
Clindamycin (CLI) 0.5-2 4 
Streptomycin (STR) 1000  
Nitrofurantoin (NIT) 32-64 128 
1,2Fosfomycin (FOS) 0.25-64 64 (EUCAST) 
1Fosfomycin susceptibility testing was performed using the agar dilution technique 
2Fosfomycin breakpoints were obtained from the European Committee on Antimicrobial Susceptibility 
testing. Breakpoints for S. aureus were used for S. pseudintermedius 
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3.3.3 Molecular investigation 
DNA was crudely extracted for PCR by boiling. From fresh overnight culture, four 
to five bacterial colonies were transferred to 200 L of sterile water and heated at 95C 
for ten minutes. The resulting suspension was spun down and the supernatant removed 
and stored at -20C prior to use. If resistance phenotypes involved third generation 
cephalosporins, cephamycins, fluoroquinolones or fosfomycin (E. coli) or oxacillin or 
fosfomycin (S. pseudintermedius), isolates were sequentially screened for various 
resistance genes by PCR. General PCR conditions included denaturation at 94C for 6 
minutes followed by 30-35 cycles of denaturation (94C), annealing (various 
temperatures), and extension (72C) for 1 minute each. All reactions included a final 
extension step for 10 minutes at 72C. All PCR reactions included a no template 
negative control and where possible, a positive control containing DNA from an isolate 
previously determined to be positive for the gene of interest. Primers and associated 
annealing temperatures utilized for all reactions are shown in Table 3.3. 
3.3.3.1 Fosfomycin inactivating enzymes 
Isolates displaying MICs above the EUCAST epidemiological cut-off of 16 
g/mL (for E. coli) and 64 g/mL (for S. pseudintermedius) were screened for 
transferable fosfomycin resistance genes by PCR. E. coli were screened for fosA, fosA3 
and fosC2, while S. pseudintermedius were screened for fosB using specific primers 
outlined in Table 3.3. 
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3.3.3.2 S. pseudintermedius 
 Oxacillin resistant S. pseudintermedius isolates were screened for mecA using 
primers outlined in Table 3.3.  
3.3.3.3 E. coli 
All third-generation cephalosporin (ceftriaxone or ceftiofur) resistant E. coli 
isolates were initially screened using universal primers for CTX-M type enzymes. Any 
positive isolates were sequentially screened for CTX-M groups 1, 2, 8 and 9, using 
primers described previously. Isolates were additionally screened for the SHV and TEM 
type ESBLs. Cephamycin (cefoxitin) resistant isolates were screened for CMY-2 type 
AmpC -lactamase production. (Fluoro)quinolone resistant E. coli isolates were 
screened for each of the PMQR determinants; qnrA, qnrB, qnrS, aac(6′)-Ib-cr, and 
qepA. The primers and associated annealing temperatures used for all reactions are 
outlined in Table 3.3. 
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Table 3.3: Primers and PCR conditions 
Name Nucleotide sequence (5’-3’) Amplicon 
size 
Annealing 
Temperature 
(C) 
Reference 
16S 
(1476/1478) 
GAGTTTGATCCTGGCTCAG  500 60C 261 
G(TA)ATTACCGCGGC(TG)GCTG 
AAC(6’)-IB-
CR 
CATTGTAGCACGTGTGTA 482 67C 264 
CATTGTAGCATGCG'I"I'GAAG 
CMY-2 ATGATGAAAAAATCGTTATGCTGC 1000 68C 266 
GCTTTTCAAGAATGCGCCAGG 
CPN60 
(1594/1595) 
CGCCAGGGTTTTCCCAGTCACGACGACGTCGCCGGTGACGGCACCACCAC 700 57C 260 
AGCGGATAACAATTTCACACAGGACGACGGTCGCCGAAGCCCGGGGCCTT 
CTX-M G1 GTTGTTAATTCGTCTCTTCC 700 61C 267,268 
AGTTTCCCCATTCCGTTTC 
CTX-M G2 ACTCAGAGCATTCGCCGCTCA 1000 58.3C 268 
TTATTGCATCAGAAACCGTG 
CTX-M G8 CGCTTTGCCATGTGCAGCACC 307 64C 269 
GCTCAGTACGATCGAGCC 
CTX-M G9 GACCGTATTGGGAGTTTGAG 600 48C 270,271 
ATCTGATCCTTCAACTCAGC 
CTX-M U ATGTGCAGYACCAGTAARGTKATGGC 593 61C 267 
TGGGTRAARTARGTSACCAGAAYCAGCGG 
FOSA ATCTGTGGGTCTGCCTGTCGT 271 59.5C 147 
ATGCCCGCATAGGGCTTCT 
FOSA3 CCTGGCATTTTATCAGCAGT 234 58C 146 
CGGTTATCTTTCCATACCTCAG 
FOSB TTTTGAGCTTGCAGGCCTAT 420 60C * 
ATGACCATCAGGGTCGGTAA 
FOSC2 TGGAGGCTACTTGGATTTG 217 50.5C 147 
AGGCTACCGCTATGGATTT 
MECA TCCAGATTACAACTTCACCAGC 250 52C 292 
CCACTTCATATCTTGTAACG 
ACCAATGCTTAATCAGTGAG 
QEPA GCAGGTCCAGCAGCGGGTAG 199 60C 272 
CTTCCTGCCCGAGTATCGTG 
QNRA ATTTCTCACGCCAGGATTTG 516 53.4C 273 
GATCGGCAAAGGTTAGGTCA 
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QNRB GATCGTGAAAGCCAGAAAGG 469 67C 
ACGATGCCTGGTAGTTGTCC 
QNRS ACGACATTCGTCAACTGCAA 417 53C 
TAAATTGGCACCCTGTAGGC 
SHV TTATCTCCCTGTTAGCCACC 797 68C 274 
GATTTGCTGATTTCGCTCGG 
TEM GCGGAACCCCTATTTG 964 58.3C 275 
ACCAATGCTTAATCAGTGAG 
*Primers designed using Primer3 based off of sequence from ARGANNOT accession number AHLO01000073:63139-63558:417 (2016) 
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3.3.3.4 PCR purification and sequencing 
Following PCR reactions, amplicons were further purified using the EZ-10 Spin 
Column PCR Purification Kit, (Bio Basic Canada Inc) according to the manufacturer’s 
instructions. DNA sequencing was performed by Macrogen Inc. Obtained sequences 
were compared to reference genes published in the NCBI and CARD databases using 
the BLAST algorithm. 
3.3.3.5 Conjugation study 
To identify plasmids bearing fosfomycin resistance genes conjugation studies 
were performed on all fosfomycin resistant E. coli, using an azide resistant strain (E. coli 
J53) as a recipient. In short, Muller-Hinton agar plates were prepared containing the 
following combinations of antimicrobial compounds; azide alone (100 g/mL), 
fosfomycin at 16 g/mL (high), fosfomycin at 4 g/mL (low), fosfomycin high (16 g/mL) 
+ azide (100 g/mL), and fosfomycin low (4 g/mL) + azide (100 g/mL). From a fresh 
overnight culture, one or two colonies were inoculated in 2 mL of TSB broth and 
incubated at 35C for three hours. Following incubation, 800 μL of recipient broth (J53) 
was combined with 200 μL of donor broth (test isolate) in 2 mL of fresh TSB and 
incubated overnight at 35C. For quality control, 10 L of each isolate (test and E. coli 
J53) in broth was sub cultured onto each of the five antimicrobial containing media and 
incubated overnight at 35C. Once quality control plates were confirmed to perform as 
expected, 200 μL of each conjugation mixture was sub-cultured onto Muller-Hinton agar 
containing azide (100 g/mL) + fosfomycin (16 g/mL) and azide (100 g/mL) + 
fosfomycin (4 g/mL) and incubated overnight at 35C. Where positive growth occurred, 
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transconjugates were plated onto both MacConkey and blood agar. Following an 
additional night of incubation, transconjugates were save back in TSB + 15% glycerol at 
-80C for later analysis.  
3.3.4 Statistical Analysis 
The Fisher’s exact test (p<0.01) was used to identify associations between 
fosfomycin and resistance to other antimicrobial compounds, as well as to the 
microbiological parameters MDR and pan-susceptibility to all other antimicrobials 
besides fosfomycin.   
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3.4 Results 
3.4.1 Microbiological analysis and inclusion criteria 
From October 1st, 2013 to July 1st, 2016, 337 E. coli isolates and 245 S. 
pseudintermedius isolates were obtained from PDS as part of ongoing surveillance 
efforts by our group. Non-urine, non-canine, non-E. coli or non-S. pseudintermedius and 
repeat isolates were excluded leaving a total of 274 canine urinary E. coli and 113 S. 
pseudintermedius isolates. 
3.4.2 Antimicrobial susceptibility testing 
Susceptibility to fosfomycin exceeded 97% among the 387 isolates tested. 
Overall, 7 (2.6%) E. coli and 4 (3.5%) S. pseudintermedius isolates were resistant 
(Figure 3.1). One fosfomycin resistant E. coli was MDR. Three of the fosfomycin 
resistant isolates were pan-susceptible to all other antimicrobials tested (Table 3.4). A 
statistically significant association (p<0.01) was found between resistance to fosfomycin 
and resistance to cefoxitin as shown in Table 3.5.  
Of the four fosfomycin resistant S. pseudintermedius, 75% were also methicillin 
resistant (Table 3.4). A statistically significant relationship (p<0.01) was found between 
resistance to fosfomycin and resistance to oxacillin, clindamycin, gentamicin, the 
fluoroquinolones (levofloxacin, moxifloxacin and ciprofloxacin) and MDR as shown in 
Table 3.6. 
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3.4.3 Detection and transferability of resistance genes 
 None of the fosfomycin resistance genes fosA, fosA3, fosC2 or fosB were 
detected in our resistant isolates. A single fosfomycin resistant E. coli was found to 
produce the CMY-2 type AmpC -lactamase and all three fosfomycin resistant MRSP 
possessed the mecA gene as shown in Table 3.4. Transmission of fosfomycin 
resistance was not found to occur between our resistant isolates and recipient E. coli 
J53 as determined by conjugation studies.  
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Figure 3.1: An fosfomycin MIC distribution of canine urinary E. coli (n=274) and S. pseudintermedius (n=113) isolates 
collected between October 2013-July 2016. Breakpoints (indicated by the red line) are based off of published EUCAST 
guidelines 
0
5
10
15
20
25
30
35
40
45
<0.25 0.5 1 2 4 8 16 32 64 >64
F
re
q
u
e
n
c
y
 (
%
)
Minimum inhibitory concentration (g/mL)
A Fosfomycin MIC distribution for E. coli and S. pseudintermedius 
isolated from canine urinary tract infections in Saskatoon, SK
S. pseud
E. coli
 - 130 - 
Table 3.4: Phenotypic and genomic characteristics of fosfomycin resistant E. coli and S. pseudintermedius isolated from 
canine urinary samples 
Isolate Phenotype Genotype 
E. coli 
ECPDS22 FOS  
ECPDS84 FOS  
ECPDS109 FOS + AMP + AUG + FOX + AXO + XNL + TET CMY-2 
ECPDS114 FOS + AMP  
ECPDS177 FOS  
ECPDS249 FOS + FOX + NAL + CHL + SOX  
ECPDS304 FOS + AMP + AUG + AMP  
S. pseudintermedius 
SPPDS36 FOS + GEN + SXT + ERY + OXA + AMP + PEN+ LEVO + MXF + CLI + 
CIP 
mecA 
SPPDS81 FOS   
SPPDS87 FOS + SXT + ERY + OXA + AMP + PEN + LEVO + MXF + CLI + CIP mecA 
SPPDS130 FOS + GEN + RIF + SYN + OXA + AMP + PEN + CLI mecA 
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Table 3.5: Fisher’s exact test (p<0.01) for association between fosfomycin resistance and resistance to other antimicrobial 
classes among E. coli (n=274) 
Antimicrobial Number resistant (# co resistant to FOS) p value 
AMP 39 (3) 0.0622 
AUG 12 (2) 0.0327 
FOX 14 (3) 0.0033* 
AXO 10 (1) 0.2314 
XNL 10 (1) 0.2314 
NAL 16 (1) 0.3469 
CIP 3 (0) 1.00 
GEN 6 (0) 1.00 
TET 23 (1) 0.4625 
CHL 9 (1) 0.2106 
SOX 26 (0) 1.00 
SXT 5 (0) 1.00 
AZI 5 (0) 1.00 
1Pan susceptible 214 (3) 0.0432 
MDR 20 (1) 0.4153 
1These isolates were susceptible to all antimicrobials besides fosfomycin. 
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Table 3.6: Fisher’s exact test (p<0.01) for association between fosfomycin resistance and resistance to other antimicrobial 
classes among S. pseudintermedius (n=113) 
Antimicrobial Number resistant (# co resistant to FOS) p value 
PEN 68 (3) 1.00 
AMP 44 (3) 0.2973 
OXA 4 (3) 0.0001* 
TET 25 (0) 0.5739 
CHL 3 (0) 1.00 
ERY 6 (2) 0.0135 
CLI 4 (3) 0.0001* 
GEN 4 (2) 0.0056* 
LEVO 2 (2) 0.0009* 
MXF 2 (2) 0.0009* 
CIP 2 (2) 0.0009* 
SXT 6 (2) 0.0135 
RIF 1 (1) 0.0354 
SYN 1 (1) 0.0354 
1Pan susceptible 40 (1) 1.00 
MDR 9 (3) 0.0014* 
1These isolates were susceptible to all antimicrobials besides fosfomycin.  
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3.5 Discussion and Conclusion 
As AMR continues to emerge in uropathogens, the importance of alternative 
therapeutic options such as fosfomycin increases in both human and veterinary 
medicine69. Currently, fosfomycin is recommended as an appropriate first line option for 
the treatment of uncomplicated cystitis caused by susceptible E. coli and E. faecalis in 
human medicine64.  However, in the corresponding veterinary guidelines published by 
ISCAID, fosfomycin is reserved for the treatment of infections where MDR has been 
documented54. The results of the current investigation indicate that canine urinary E. coli 
in Saskatchewan are exceptionally susceptible to fosfomycin. Overall, these findings are 
consistent with resistance rates reported in other investigations. In human medicine, the 
microbiological and clinical literature summarizing the efficacy of fosfomycin against 
Enterobacteriaceae has been reviewed78. Of 13 microbiological studies, 10 looked 
exclusively at community or hospital acquired UTIs where the vast majority of isolates 
were ESBL producing E. coli. All ten studies reported susceptibility rates in excess of 
90%79–88. Though the number of studies is limited in veterinary medicine, rates of 
susceptibility in excess of 97% are consistently reported96,97,146,293. Unfortunately, none 
of these investigations have looked exclusively at fosfomycin resistance among urinary 
E. coli. Fosfomycin is not labeled for use in companion animals and any veterinary use 
of this antimicrobial is therefore extra-label. In fact, the limited use of fosfomycin in 
veterinary medicine may be attributed to its formulation as a powder to be dissolved in 
water and taken orally once. Administration of this dose to canine patients therefore 
requires the use of a stomach tube that is generally not practical for uncomplicated 
cystitis cases in the face of more convenient oral formulations. 
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Similar to E. coli, our results indicate that canine urinary S. pseudintermedius are 
highly susceptible to fosfomycin. Though it is used much less commonly for the 
treatment of Gram-positive infections, in human medicine, methicillin susceptible and 
MRSA, penicillin resistant S. pneumoniae and vancomycin resistant Enterococci (VRE) 
have demonstrated high rates of susceptibility to fosfomycin70. In the present study we 
report a statistically significant relationship between methicillin and fosfomycin 
resistance. In fact, three out of the four MRSP isolates in our study were fosfomycin 
resistant and MRSP accounted for 75% (n=4) of fosfomycin resistant S. 
pseudintermedius isolates. This finding is supported by investigations into fosfomycin 
resistance among methicillin susceptible (MSSP) and resistant S. pseudintermedius 
causing canine pyoderma98,99. Specifically, while susceptibility among MSSP remained 
close to 100%, fosfomycin resistance among MRSP is closer to 15%98,99. However, 
given the low frequency of fosfomycin resistant S. pseudintermedius (n=4) identified in 
the present investigation, these results must be interoperated with caution. 
In the present study, we did not identify any of the transmissible resistance genes 
fosA, fosA3, fosB or fosC2 among our isolates. What’s more, though we did find a 
statistically significant relationship between fosfomycin and cefoxitin resistance, 
including one fosfomycin resistant E. coli, which coharbored a CMY-2 type AmpC -
lactamase, this relationship should be interoperated with caution due to small sample 
size. Interestingly, an association between CTX-M production and fosfomycin resistance 
has been previously reported among fosfomycin resistant E. coli of animal 
origin144,145,147,294,295. Considering the limited use of fosfomycin in companion animals, 
this affiliation is concerning as it supports the ability of E. coli to acquire incidental 
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fosfomycin resistance following treatment with common first line agents such as the -
lactams.  
Despite the absence of inactivating enzymes, there are multiple alternative 
mechanisms, which may account for the fosfomycin resistance observed in this 
study103.  In E. coli, decreased uptake and target modification by chromosomal 
mutations in the murA gene have been described76,103. Specifically, mutations in the 
hexose phosphate (uhpA and uhpT genes) and glycerol 3 phosphate (glpT gene) 
transporter system involved in fosfomycin uptake, lead to decreased susceptibility or 
clinical resistance. These mechanisms may provide the basis for future molecular 
investigations of fosfomycin resistance within our isolate population. Interestingly, fosB 
has been reported to be highly prevalent (87%) among MRSP isolates, even in the 
absence of fosfomycin resistance98. However, we did not identify fosB among the S. 
pseudintermedius isolates investigated in this study. Additional studies are required to 
further elucidate this relationship in Staphylococci. 
Limitations in the present investigation are mainly methodological and include 
first and foremost a limited sample size and relatively low frequencies of resistant 
isolates. There is also an overall lack of information regarding fosfomycin resistance in 
S. pseudintermedius in the literature. Specifically, the lack of an established species-
specific breakpoint for S. pseudintermedius may have led to the inaccurate phenotypic 
categorization of isolates as resistant.  
In conclusion, the increasing rate of AMR among the companion animal 
pathogens E. coli and S. pseudintermedius mirrors the emergence of resistance seen in 
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human infectious disease. Our results indicate that fosfomycin resistance, including 
transferrable resistance mechanisms, is not yet common in canine urinary pathogens. 
However, continued surveillance is required to identify changes.  
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4. GENERAL DISCUSSION AND CONCLUSION 
 Canine urinary pathogens in Saskatchewan remain susceptible to clinically 
relevant first line therapies, including the alternative agent fosfomycin. Except for 
ampicillin, resistance rates remain below 10% for all agents designated by ISCAID as 
either first line or alternative treatments for canine UTIs. Concerning resistance 
mechanisms that have become common place among human urinary E. coli have only 
recently been detected in this region, including ESBL producers, isolates possessing 
PMQR determinants, and members of the MDR pandemic lineage E. coli ST131. 
Resistance to the carbapenems, considered a last resort treatment for a variety of MDR 
Gram-negative infections in humans, was not detected. The significance of these 
findings resonates within the disciplines of public health, clinical veterinary medicine and 
epidemiology.  
 The public health threat posed by dogs (and other companion and production 
animals) in the zoonotic transmission of AMR genes has gained interest in recent years. 
Though strain sharing has been confirmed by molecular techniques in some instances, 
the direction of transmission remains poorly understood. In an attempt to quantify the 
contribution of animal sources to the human AMR problem, a sample of international 
microbiology experts were qualitatively surveyed245. Based on the results, among 
critically important human pathogens, the perceived involvement of animal reservoirs 
was estimated to be <4% and the majority of contributing diseases identified by 
specialists were well established zoonoses245. Various investigations have also 
highlighted significant discrepancies in the phenotypic and genomic resistance profiles 
of human and animal derived ExPEC. For example, the prevalence of ST131 is 
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particularly high among fluoroquinolone resistant E. coli of human origin (35%) 
compared to those from companion animals (7.2%)296,297. What’s more, ESBL producing 
Enterobacteriaceae isolated in animals appear to be largely distinct form those 
encountered in humans103. These findings provide support for a relatively minor 
contribution of animal reservoirs to the AMR problem in human medicine, or, at the very 
least point to a more complex epidemiology of AMR emergence and dissemination in 
humans and animals. 
 On a global scale, the frequency of resistance in urinary E. coli in this region is 
comparable to results obtained in northern European countries including Denmark and 
Sweden212,214. The low frequency of resistance detected in this investigation is 
encouraging, as surveillance efforts so often represent a reactive as opposed to a 
proactive approach to the problem of AMR. Low levels of baseline resistance are 
informative for detecting resistance and classifying the molecular mechanisms 
responsible. As a natural phenomenon, the “novelty” of AMR is often measured only 
with respect to clinical relevance. In other words, resistance mechanisms that are 
believed to be newly described in clinical isolates are often not new at all and turn out to 
be prevalent once efforts to detect them are initiated. For example, the first case of 
mobile colistin resistance (mcr-1) from a commensal porcine E. coli isolate in China 
motivated an investigation into clinical Enterobacteriaceae isolates from hospital 
inpatients that revealed a low-level presence of mcr-1 (~1%)298.  A susceptible 
population of clinical isolates like the one collected in this investigation, provides an 
excellent resource for retrospective investigations into these newly emerging resistance 
mechanisms. 
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 There is significant pressure on veterinary professionals to use antimicrobials 
judiciously based on the perceived inappropriate use of these drugs in animals15. In the 
face of diagnostic uncertainty, pressure by owners and concern for secondary infections, 
local surveillance data and infection specific treatment guidelines provide support for 
clinicians in making empirical decisions regarding AMU30. In general, the “10% rule” is a 
useful starting point for interoperating surveillance data50. Where the frequency of 
resistance exceeds 10%, care must be taken in selecting an appropriate agent for 
empirical treatment. The case of amoxicillin resistance in human urinary E. coli is an 
excellent example of the value of surveillance data. Removed from the IDSA guidelines 
for UTI treatment in 1999 due to concern for resistance, twenty years later, this 
investigation identified an average ampicillin resistance frequency of 14% for canine 
urinary E. coli across the four-year surveillance study. While this figure exceeds the 10% 
rule generally used to guide interpretation of surveillance data, amoxicillin’s tendency to 
concentrate in the urine, coupled with the relatively low rates of resistance reported 
here, support its continued use in the empirical treatment of canine UTIs209.  However, 
surveillance data is not a replacement for appropriate diagnostic work up or clinical 
judgment and must be interoperated within the clinical context. For example, the 
treatment of bacteriuria in the absence of clinical signs is considered unnecessary in the 
majority of cases in human medicine299. Similar care must be taken in selecting 
appropriate antimicrobials in recurrent or persistent UTIs, where underlying pathology 
complicates treatment249. In the end, decision making around AMU is complex in 
veterinary medicine and incorporates additional factors related to cost, commission, 
client convenience and availability, which may prevail even in the face of an emerging 
AMR problem. 
 - 140 - 
4.1 Limitations 
  The limitations of this investigation can be broken into methodological and 
epidemiological. With respect to susceptibility testing, the broth microdilution and agar 
dilution methods used here, are both considered gold standard for the respective agents 
under investigation. However, it is possible that isolates displaying MICs which border 
on resistant may have been incorrectly classified based on the accuracy of the Sensititre 
AIM system used in this study. In order to get approved by the FDA, commercial devices 
must be accurate to within one double dilution, reporting false susceptible and false 
resistant results <1.5% and <3% of the time respectively59. Therefore, inaccurate MICs 
can be expected up to 1.5% or 3% of the time. An additional limitation associated with 
susceptibility testing is the interoperative criteria. Ideally, breakpoints take into account 
the pharmacokinetics of a specific drug formulation, at the specified label dose, in the 
veterinary species of interest, as well as clinical data on the likelihood of success in 
eradicating an infection in a particular body site59. Unfortunately, the published criteria 
for veterinary species, specifically dogs, is incomplete for many antimicrobials and is 
extrapolated from human data. For the purposes of surveillance and describing the 
frequency of in vitro resistance, we used the CLSI guidance document published for 
human infections throughout this study262. Therefore, it is possible that our interpretation 
of AMR is not reflective of clinical efficacy in this species. The only agent for which a 
urine specific breakpoint was used was for fosfomycin and E. coli. At the time of 
susceptibility testing, the only breakpoint available for fosfomycin (>32 g/mL) was 
through EUCAST and this breakpoint differs from the one subsequently published by 
CLSI ( 256 g/mL)262. What’s more, there is currently no species-specific breakpoint for 
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fosfomycin against S. pseudintermedius, and thus we used the published value for the 
Staphylococcus spp. genus as a whole. To offset the potential error introduced by these 
breakpoints, we used the EUCAST epidemiological cut off values as a guide for our 
molecular investigation, to ensure that we captured all isolates with an MIC value above 
what would be expected in wild type E. coli or Staphylococci isolates. 
 The primary objective of this study was to identify and describe the frequency of 
AMR among urinary E. coli. However, a secondary aim included the molecular 
characterization of transferrable resistance to antimicrobials considered important for 
treating sporadic cystitis, namely -lactams, fluoroquinolones and fosfomycin. Given the 
restricted nature of this part of the investigation there are many limitations to consider, 
which are largely outside the scope of a surveillance study. First, in cases were -
lactamases and PMQR determinants were not detected, it would have been interesting 
to pursue other resistance mechanisms including SNPs in the parC and gyrA genes 
encoding the antimicrobial target of fluoroquinolones and other broad spectrum -
lactamases such as additional CTX-M and other AmpC (CMY-1, FOX, ACT, MOX, ACC, 
DHA) type enzymes. To confirm transferability, it might have been beneficial to perform 
conjugation studies. However, given the surveillance nature of this study, as well as the 
substantial evidence for the localization of ESBLs and PMQR genes on plasmids, such 
studies were deemed unnecessary. Many additional fosfomycin resistance mechanisms 
have also been described in E. coli including decreased uptake and target modification 
by chromosomal mutations in the murA gene76,103. Specifically, mutations in the hexose 
phosphate (uhpA and uhpT genes) and glycerol 3 phosphate (glpT gene) transporter 
systems could have been investigated. The DNA fingerprinting technique chosen in this 
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study, MLST, is also a potential limitation. While alternative “gold standard” strain typing 
methods, including WGS and PFGE may be considered superior, MLST allowed us to 
optimize cost and efficiency, while still providing adequate resolution105-106. Specifically, 
our exclusive interest in E. coli made MLST an appropriate technique, as it is able to 
discriminate between isolates of the same species. Unfortunately, MLST does not 
provide sufficient discrimination for all typing purposes, including resolving differences 
among single-clone organisms, as might be necessary in outbreak scenarios101. 
However, our interest in exploring the regional relatedness of MDR E. coli isolates to 
globally important strains, (ST131) makes this high level of resolution unnecessary.  
A clearly defined objective is often overlooked in the planning and implementation 
of AMR surveillance initiatives. Specific goals can range from describing resistance in 
time and space, to identifying risk factors, to reporting the clinical or microbiological 
outcome of infections149. The inclusion criteria of the present investigation were simple 
and incorporated first time positive cultures for E. coli from canine urine samples over a 
four-year period. Previous AMU or other epidemiological information such as 
microbiological cure, clinical cure or underlying co morbidities were not considered. 
While this information would be considered if the goal was to ascertain risk factors for 
UTIs in canine patients, the objective, in this case, was strictly to identify and describe 
resistance in this region. However, additional sources of bias inherent in surveillance 
type studies must be considered, including case definitions, case ascertainment, 
sampling bias, multiple counting and laboratory procedures149. In the current 
investigation, case ascertainment and sampling bias are particularly important. As our 
data collection was based on convenience sampling of laboratory isolates, we failed to 
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collect certain samples fitting our case definition of uncomplicated canine UTIs caused 
by E. coli. What’s more there is inherent sampling bias in passive surveillance studies of 
laboratory isolates, as this population is bias towards infections where empirical 
treatment has likely failed, leading to the submission of samples for culture and 
susceptibility. On the other hand, a combination of our strict inclusion criteria and robust 
methodology assisted in eliminating bias related to poor or incomplete case definitions, 
multiple counting of the same case, and laboratory procedures.  
 
4.2 Future Directions 
The development of this collection of canine urinary E. coli isolates allows for 
many microbiological and clinical questions to be investigated in the future. For 
example, this study does not address the interrelatedness between AMU and AMR. 
Acquiring and overlaying AMU data from medical records in future studies would allow 
for the association between previous antimicrobial exposure and the development of 
resistance to be investigated. What’s more, with this clinical data, additional measures 
including clinical and microbiological efficacy may be established for various agents in 
treating uncomplicated cystitis in canine patients.  
This investigation also did not consider how additional patient factors such as 
signalment, co-morbidities or underlying pathology might be contributing to the 
emergence of resistance. For example, exploring the resistance patterns among 
complicated and recurrent infections would be interesting to establish whether these 
infections are truly more MDR or if it is more likely a pathology or pharmacological 
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problem leading to treatment failure. It would also be interesting to perform a stratified 
analysis of certain populations including ESBL producers and ST131 isolates to try to 
establish the risk factors or resistance determinants associated with these infections.  
Additional molecular investigations, including characterizing plasmids, confirming 
transmissibility by conjugation studies and obtaining more complete resistance genes 
profiles would also be informative. For example, efflux pump encoded by the tet and floR 
genes confer resistance to tetracyclines and phenicols respectively, while the folic acid 
metabolic enzymes encoded by sul and dfr genes result in resistance to trimethoprim 
and sulfonamides103. Additional inactivating enzymes encoded by tetX and cat genes 
confer tetracycline and chloramphenicol resistance to E. coli respectively. Finally, there 
are additional SNPs in antimicrobial targets to consider, including the rmt and armA 
genes that convey aminoglycoside resistance, as well as the parC and gyrA genes that 
lead to decreased fluoroquinolone susceptibility or resistance103. There are also many 
mechanisms left to explore regarding fosfomycin resistance in E. coli103. Characterizing 
SNPs in the hexose phosphate and glycerol 3 phosphate transporter systems encoded 
by uhpA, uhpT and glpT genes lead to decreased fosfomycin uptake and resistance, as 
does target modification by chromosomal mutations in the murA gene76,103. PCR primers 
and conditions have been established previously for investigating these highly 
conserved genes in E. coli286. In fact, the extremely low number of fosfomycin resistant 
isolates identified (n=11) made WGS a viable option in this study. However, as the 
evidence for a connection between a SNP in one of these targets and phenotypic 
resistance is limited, the cost benefit ratio of performing WGS was considered 
unfeasible. 
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In human medicine there has been a lot of focus on the virulence factors and 
pathotypes of ExPEC22,115,296,300,301. Characterizing our isolates in this manner could 
answer questions related to the pathogenicity or virulence of canine urinary E. coli, as 
well as establish whether certain resistance genes are associated with certain 
pathotypes or virulence genes. Finally, as we know that resistance develops rapidly, but 
is often maintained and declines comparably slowly in a region or population, 
understanding the fitness costs associated with maintaining resistance genes and 
virulence factors is another interesting question to be pursued in the future.  
 
4.3 Conclusion 
 Transmissible AMR mechanisms including ESBLs and PMQR genes are not yet 
common among canine urinary E. coli in Saskatchewan and these isolates remain highly 
susceptible to recommended empirical treatment options. Though it is considered a 
second line option by ISCAID, the alternative agent fosfomycin displays exemplary in 
vitro efficacy against both E. coli and S. pseudintermedius isolated from canine UTIs. 
Despite these optimistic results, consensus statements in veterinary medicine demand 
for more judicious use of antimicrobials, while the geographical variations in AMU and 
AMR require clinicians to be aware of emerging resistance in their practice area15,49,50.  
The findings generated by this research strives to fill this significant knowledge gap for 
practicing veterinarians and provide a baseline and blueprint for developing future AMR 
surveillance studies for companion animal pathogens in Canada.  
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